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Adenoidectomy with or without grommets for children with
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3Medical Research Council Institute of Hearing Research, Glasgow Royal Inﬁrmary, Glasgow, UK
4evidENT, University College London, Ear Institute, London, UK
5Department of Otorhinolaryngology, John Radcliffe Hospital, Oxford, UK
*Corresponding author
Background: Otitis media (OM) is a leading cause of medical consultations, antibiotic prescription and
surgery in children. The surgical procedures offered to children with recurrent or persistent OM are
insertion of grommets, adenoidectomy or a combination of the two. There is clear National Institute for
Health and Care Excellence guidance for the use of grommets in subgroups of children with persistent OM
with effusion (OME), but similar guidance is not available for adenoidectomy, either in persistent OME or
in recurrent acute OM (AOM).
Objectives: (1) To develop a model to predict the risk of children referred for adenoidectomy having a
prolonged duration of their OM. Then, (2a) to evaluate the overall effect of adenoidectomy, with or
without grommets, on OM using individual patient data (IPD) and (2b) to identify those subgroups of
children who are most likely to beneﬁt from adenoidectomy with or without grommets.
Data sources: A number of electronic databases were searched from their inception including the
Cochrane Ear, Nose and Throat Disorders Group Trials Register, the Cochrane Central Register of
Controlled Trials (CENTRAL), PubMed, EMBASE, the Cumulative Index to Nursing and Allied Health
Literature (CINAHL), metaRegister of Current Controlled Trials (mRCT), ClinicalTrials.gov, International
Clinical Trials Registry Platform (ICTRP), ClinicalStudyResults.org and Google.
Review methods: Studies eligible for inclusion in this IPD meta-analysis were randomised controlled trials
in children up to 12 years of age diagnosed with recurrent AOM and/or persistent OME in which
adenoidectomy (with or without grommets) was compared with non-surgical treatment or grommets
alone. The ﬁnal selection of eligible studies and the quality assessment were carried out according to
standard methods and disagreement was resolved by discussion.
Results: A total of 503 articles were identiﬁed of which 10 trials were included in the meta-analysis; eight
of these were at a low risk of bias and two were at moderate risk. The primary outcome was failure at
12 months, deﬁned by a set of persisting symptoms and signs. In the prognostic analysis 56% of those
children referred for adenoidectomy (but randomised to the non-surgical group) failed to improve (38% of
the children with recurrent AOM and 89% of the children with persistent OME). Children who had
adenoidectomy had a greater chance of clinical improvement. The size of that effect is, in general, small
but persists for at least 2 years. Two subgroups of children are most likely to beneﬁt from adenoidectomy:
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ﬁrst, children aged < 2 years with recurrent AOM – 16% of those who had adenoidectomy failed at
12 months whereas 27% of those who did not have adenoidectomy failed [rate difference (RD) 12%,
95% conﬁdence interval (Cl) 6% to 18%; number needed to treat (NNT) = 9]; second, children aged
≥ 4 years with persistent OME – 51% of those who had adenoidectomy failed at 12 months whereas
70% of those who did not have adenoidectomy failed (RD 19%, 95% Cl 12% to 26%; NNT = 6). No
signiﬁcant beneﬁt of adenoidectomy was found in children aged ≥ 2 years with recurrent AOM and
children aged < 4 years with persistent OME.
Limitations: The need to use a composite end point and the limited number of subgroup variables that
could be studied are factors that reduce the robustness of these results; however, we do not believe that
this reduces the validity of the conclusions.
Conclusions: Adenoidectomy is most beneﬁcial in children with persistent OME aged ≥ 4 years. A smaller
beneﬁcial effect was found in children with recurrent AOM aged < 2 years. Consideration must be given to
the balance between beneﬁts and harms. Future research is required in a number of key areas, including
deﬁning the best methods of selecting, developing and administering patient-reported outcome measures
to assess the value of treatments for children with persistent OME and recurrent AOM and upper
respiratory infections; investigating the clinical effectiveness and cost-effectiveness of hearing aids (air or
bone conduction) and the use of interventions to improve classroom acoustics for children with different
degrees of persistence and severity of hearing loss associated with OME; and investigating why
professionals’ and parents’/carers’ treatment preferences vary so much both nationally and internationally.
We do not understand why adenoidectomy works in different subgroups at different ages, nor its effects
in special populations, such as children with Down syndrome. We also need further research on the impact
and optimal management of otitis media in these special situations and others, such as in children with a
cleft palate or developmental problems.
Study registration: The study is registered as PROSPERO CRD42011001549.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Acute otitis media An acute infection of the middle ear that can be viral and/or bacterial in origin and
which may result in the formation of pus and lead to an acute perforation of the tympanic membrane.
Otitis media with effusion (‘glue ear’) The presence of fluid in the middle ear behind an intact tympanic
membrane without signs and/or symptoms of an acute infection.
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Scientiﬁc summary
Background
Otitis media (OM) continues to be one of the leading causes of medical consultations and the most
frequent reason for antibiotic prescription and surgery in children in high-income countries. The surgical
procedures offered to children with recurrent or persistent OM are (1) insertion of grommets (ventilation
tubes), (2) adenoidectomy and (3) a combination of the two. Although clear National Institute for Health
and Care Excellence (NICE) guidance is available for the use of grommets in subgroups of children with
persistent OM with effusion (OME), similar guidance is not available for adenoidectomy, either in persistent
OME or in recurrent acute otitis media (AOM). NICE recognises a need for further studies documenting the
effect of adenoidectomy, either alone or as an adjuvant to grommet insertion, in the management of
recurrent or persistent OM in children. In particular, it recognised a need for studies to identify any
subgroups that might beneﬁt more or less from surgical intervention than others. An individual patient
data (IPD) meta-analysis, that is, a meta-analysis of the original individual data from previous trials, offers a
unique opportunity to identify subgroups that may be more or less likely to beneﬁt from adenoidectomy.
Objectives
In this IPD meta-analysis we therefore (1) developed a model to predict the risk of children referred for
adenoidectomy having a prolonged duration of their otitis media. Then, (2a) having evaluated the overall
effect of adenoidectomy, with or without grommets, on OM using these IPD, we (2b) identiﬁed those
subgroups of children who beneﬁt most, or who are most likely to beneﬁt, from adenoidectomy with or
without grommets.
Methods
The study was registered on 13 September 2011 in the PROSPERO register (CRD42011001549). We
searched the following databases from their inception: the Cochrane Ear, Nose and Throat Disorders
Group Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library
Issue 1, 2009, and Issue 5, 2012), PubMed, EMBASE, Cumulative Index to Nursing and Allied Health
Literature (CINAHL), Latin American and Caribbean Health Sciences Literature (LILACS), KoreaMed,
IndMED, PakMediNet, CAB Abstracts, Web of Science, BIOSIS Previews, China National Knowledge
Infrastructure (CNKI), the metaRegister of Current Controlled Trials (mRCT), ClinicalTrials.gov, the
International Clinical Trials Registry Platform (ICTRP), ClinicalStudyResults.org and Google. We used the
following keywords with their synonyms: ‘adenoidectomy’ and ‘otitis’. The ﬁrst search was completed on
30 March 2009. Thereafter we received weekly updates from PubMed and performed a full updated
search on 7 June 2012.
Studies were eligible for inclusion in this IPD meta-analysis if they were a randomised controlled trial in
children up to 12 years of age diagnosed with OM (being recurrent AOM and/or persistent OME) in which
adenoidectomy (with or without grommets) was compared with non-surgical treatment or grommets.
Desirable time points for outcome assessment were 6, 12, 18 and 24 months.
For the quality assessment of the eligible studies we used The Cochrane Collaboration’s quality assessment
(risk of bias) tool. After checking the quality of the data sets and reproducing the ﬁndings of the individual
studies, we developed one overall data set by recoding the variables from the individual data sets to the
set of variables used for the IPD meta-analysis.
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Our main comparison was adenoidectomy with or without grommets compared with non-surgical
treatment or grommets only. This comparison was selected on the basis of prior knowledge of the
available data sets included in our conventional meta-analysis, to maximise the statistical power to identify
subgroups. Secondary comparisons studied were:
1. adenoidectomy with unilateral or bilateral grommets compared with non-surgical treatment
2. adenoidectomy with unilateral or bilateral grommets compared with unilateral or bilateral grommets
3. adenoidectomy without grommets compared with non-surgical treatment
4. adenoidectomy without grommets compared with unilateral or bilateral grommets.
We did not study the following comparisons as these analyses do not fulﬁl the criteria for inclusion in this
IPD meta-analysis:
1. adenoidectomy with unilateral or bilateral grommets compared with adenoidectomy without grommets
2. unilateral or bilateral grommets compared with non-surgical treatment.
The primary outcome was failure at 12 months, which was deﬁned as one or more of the following:
l four or more AOM episodes (including episodes of otorrhoea) per year
l presence of effusion for ≥ 50% of the time (i.e. effusion for > 6 months)
l need for additional surgery
l hearing* improved by < 10 dB.
*Hearing was expressed as a mean air conduction hearing level measured by age-appropriate audiometry
(if possible averaged over 0.5, 1, 2 and 4 kHz). In all children the binaural average was taken. This includes
trials that used unilateral grommets and randomised ears rather than children.
Secondary outcomes studied were:
1. all individual items of failure at 12 months
2. number of episodes of AOM (including episodes of otorrhoea) during follow-up
3. time with effusion during follow-up measured in number of weeks
4. additional surgery during follow-up
5. average hearing loss measured in dBHL (hearing level in decibels as assessed on an audiometer)
6. improvement in hearing level of < 10 dB
7. adverse effects and events (including morbidity of surgery).
Multivariate prognostic modelling was performed to develop a model predicting the risk of children
referred for adenoidectomy but randomised to the non-surgical group having a prolonged duration of
their OM. Absolute risks of failure at 12 months were calculated using the predictors identiﬁed in the
multivariate analyses. To assess whether the effect of adenoidectomy was modiﬁed by age and indication
for surgery, we performed an analysis using a binominal model with an identity link to calculate rate
differences, a Poisson regression analysis with robust standard errors to calculate (adjusted) rate ratios (RRs)
and an analysis using a linear regression model to calculate (adjusted) mean differences. In the Poisson and
linear regression models, the independent variables were adenoidectomy, the potential effect modiﬁer
(age) and an interaction term (deﬁned as adenoidectomy times potential effect modiﬁer). We also used a
categorical dummy variable to identify each study within the regression analysis. Dependent variables were
the outcome measures mentioned above. Sensitivity analyses were performed to study the robustness of
our ﬁndings. Although analyses of other types were carried out, all analyses reported in detail here were
performed according to the intention-to-treat principle.
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Results
In total, 15 trials were eligible for inclusion in this IPD meta-analysis of which 10, including 1761
participating children, were included. The 10 trials differed in a number of ways, with the most important
being the indication for surgery, interventions studied and frequency of outcome assessment. Of the
10 included studies, eight were at a low risk of bias and two were at a moderate risk.
Of the 343 children who were referred for adenoidectomy but who were randomised to the non-surgical
groups and included in the prognostic analyses, 193 (56%) failed to improve at 12 months. The
independent predictor of failing to improve was indication. The absolute risk of failing to improve for
children with an indication of persistent OME was 89% and that for children with an indication of
recurrent AOM was 38%.
The proportion of children who failed at 12 months in the adenoidectomy group (adenoidectomy with or
without grommets) was 32% whereas the proportion of children who failed at 12 months in the no
adenoidectomy (non-surgical or grommets alone) group was 45%. The unadjusted for failure at 12 months
was –13% [95% conﬁdence interval (CI) –17% to –8%], resulting in a number needed to treat (NNT) of
eight children to prevent one failure. The adjusted RR was 0.76 (95% CI 0.69 to 0.85), which was similar to
the unadjusted RR (0.72, 95% CI 0.63 to 0.81). For all secondary outcomes, with the exception of presence
of effusion for ≥ 50% of the time in the ﬁrst 12 months, results for children in the adenoidectomy group
were also statistically signiﬁcantly better than results for those in the no adenoidectomy group.
The effects in the secondary comparisons also showed that children who have had their adenoid removed
have a greater chance of clinical improvement. The size of that effect is, in general, small but persists for at
least 2 years after surgery.
Two subgroups of children are most likely to beneﬁt from adenoidectomy. These are (1) children with
recurrent AOM aged < 2 years and (2) children aged ≥ 4 years with persistent OME. The proportion of
children aged < 2 years with recurrent AOM who failed at 12 months was 16% (44/281) in the
adenoidectomy group and 27% (120/438) in the group who did not have adenoidectomy (RD 12%,
95% CI 6% to 18%; NNT = 8; adjusted RR 0.63, 95% CI 0.47 to 0.85). In contrast, in children aged
≥ 2 years with recurrent AOM, no beneﬁt of adenoidectomy was seen; 18% (8/44) of the children in
the adenoidectomy group failed at 12 months and 3% (1/40) of the group who did not have
adenoidectomy failed (RD 16%, 95% CI 3% to 28%, in favour of no adenoidectomy; adjusted RR 4.96,
95% CI 0.69 to 35.5). The proportion of children aged ≥ 4 years with persistent OME who failed at
12 months was 51% (163/322) in the adenoidectomy group and 70% (289/415) in the group who did not
have adenoidectomy (RD 19%, 95% CI 12% to 26%; NNT = 6; adjusted RR 0.77, 95% CI 0.68 to 0.86).
In contrast, in children aged < 4 years with persistent OME, no signiﬁcant beneﬁt of adenoidectomy
was seen; 23% (30/128) of the children in the adenoidectomy group failed at 12 months and 30%
(33/111) of the group who did not have adenoidectomy failed (RD 7%, 95% CI –5% to 18%; adjusted
RR 0.98, 95% CI 0.69 to 1.38). The secondary comparisons and outcomes produced results that were in
the same direction but were less pronounced because of smaller numbers.
A series of sensitivity analyses using alternative deﬁnitions of ‘failure at 12 months’ showed similar results.
Discussion
Potential limitations of this IPD meta-analysis relate to the selection of studies, the number of subgroup
analyses performed, the variety of interventions and the lack of uniformity of outcomes in the original
studies, necessitating these being aggregated in a composite primary outcome measure – failure at
12 months. However, a set of sensitivity analyses based on alternative deﬁnitions of ‘failure’ did not result
in a different set of results.
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Our ﬁndings conﬁrm the clinical reality of two related but distinguishable entities within the spectrum of
OM across the age range birth to 12 years: recurrent AOM in younger children (aged < 2 years) and
persistent OME in older children (aged ≥ 4 years). It may not be age per se that is relevant but rather the
presence of differing pathophysiological mechanisms in different age groups that serve as the modiﬁer,
with age simply being a proxy for those. The mechanisms may include a relatively immature immune
response, in particular in children aged < 2 years. As the immune response improves with age, problems
with infection may recede and those associated with middle ear effusion, for example hearing loss,
become relatively more apparent. This coincides with a period of social and behavioural change in the
child’s life. Starting school and becoming part of a peer group may be the factors that initiate concerns
about performance and increase awareness of the child’s hearing. More insight into the pathophysiology
of OM is needed to understand better the causal mechanism of the subgroup effects.
Conclusion
Children with OM who have their adenoid removed have a greater chance of clinical improvement:
eight children need to receive adenoidectomy to prevent one failure. Adenoidectomy is most beneﬁcial
in children aged ≥ 4 years with persistent OME (six children needing adenoidectomy to prevent one
failure). A smaller beneﬁcial effect was found in children with recurrent AOM aged < 2 years (nine
children needing adenoidectomy to prevent one failure). No beneﬁcial effect was seen in children aged
< 4 years with persistent OME or in those aged ≥ 2 years with recurrent AOM.
The need to use a composite end point and the limited number of subgroup variables that could be
studied are factors that reduce the robustness of these results but these do not, we believe, reduce the
validity of the conclusions.
As with all interventions (and in particular in the case of surgical procedures), consideration must be given
to the balance between beneﬁts and harms. Clinicians can discuss these issues with the parents of children
with OM to allow them to make an informed treatment decision.
Future research is required in a number of key areas, including deﬁning the best methods of selecting,
developing and administering patient-reported outcome measures to assess the value of treatments for
children with persistent OME and recurrent AOM and upper respiratory infections; investigating the clinical
effectiveness and cost-effectiveness of hearing aids and the use of interventions to improve classroom
acoustics for children with different degrees of persistence and severity of hearing loss associated with
OME; and investigating why professionals’ and parents’/carers’ treatment preferences vary so much both
nationally and internationally. We do not understand why adenoidectomy works in different subgroups at
different ages, nor its effects in special populations, such as children with Down syndrome. We also need
further research on the impact and optimal management of otitis media in these special situations and
others, such as in children with a cleft palate or developmental problems.
Study registration
This study is registered at PROSPERO as CRD42011001549.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background and introduction
Otitis media (OM) continues to be one of the leading causes of medical consultations and the mostfrequent reason for antibiotic prescription and surgery in children in high-income countries.1 The
surgical procedures offered to children with recurrent or persistent OM are (1) insertion of grommets
(ventilation tubes), (2) adenoidectomy and (3) a combination of the two. Two clinical conditions, although
distinctly deﬁned, are in fact closely related and can overlap. In young children, acute otitis media (AOM) is
one of the most common causes of illness. AOM is deﬁned as the presence of ﬂuid in the middle ear with
signs and symptoms of an acute infection.2 Although many children have occasional AOM, an important
group of children suffer from recurrent episodes, deﬁned here as three or more AOM episodes in 6
months or four or more episodes in 1 year. These recurrent AOM episodes cause considerable distress to
children and their parents, through frequent episodes of acute ear pain, fever and general illness. Children
and parents experience sleepless nights and time is lost from nursery or school and from work.3,4
Otitis media with effusion (OME, ‘glue ear’) is deﬁned as the presence of ﬂuid in the middle ear behind an
intact tympanic membrane without signs and symptoms of an acute infection. It is most common in young
children, with a bimodal peak around 2 and 5 years of age. In total, 80% of children will have had a least
one episode of OME by the age of 10 years. The main symptom of OME is impaired hearing because the
middle ear effusion causes a conductive hearing loss.2
Children with persistent OME are prone to recurrent AOM episodes, and after an AOM episode all children
suffer from OME for some time. As such, children with recurrent AOM not only suffer pain and discomfort
during the acute episodes, but also experience OME-related hearing difﬁculties that may impact on their
language, behaviour and progress at school.5 It is known that the impact of recurrent AOM on a child’s
quality of life is equivalent to that of chronic conditions such as asthma.6,7
Although clear National Institute for Health and Care Excellence (NICE) guidance2 is available for the use of
grommets in subgroups of children with persistent OME, it is not the case for the use of adenoidectomy,
either in persistent OME or in recurrent AOM. NICE suggests that clinicians should consider the possible
beneﬁts of adenoidectomy in children selected for grommets for OME who also suffer from coexisting
respiratory symptoms. However, NICE2 recognises a need for further studies documenting the effect of
adenoidectomy, either alone or as an adjuvant to grommet insertion, in the management of recurrent or
persistent OM in children. In particular, NICE identiﬁed a need for studies to identify any subgroups who
might beneﬁt more or less than others from surgical intervention. We know that adenoidectomy or
adjuvant adenoidectomy is routinely performed in many countries for recurrent or persistent OM, but the
concern of NICE2 reﬂects the knowledge that the practice is not backed by high-quality scientiﬁc evidence.
The adenoid is an aggregate of lymphoid tissue located in the nasopharynx. With an extensive system of
folds and crypts on its surface, the adenoid traps viruses and bacteria that pass through the upper airways.
As part of the immune system, the adenoid plays an important role in the body’s immune response to
infectious microorganisms that pass through the upper airways. Although many of these microorganisms
may simply be transient passengers, the adenoid may serve as a reservoir for a diverse microbial
community, resulting in upper respiratory infections. Because the adenoid lies next to the oriﬁces of
the Eustachian tubes, it has long been recognised as an important factor in the pathogenesis of OM.
Microorganisms may spread via the Eustachian tube to the middle ear and cause acute, recurrent or
chronic infections. Adenoidectomy is thought to improve middle ear function by removing or reducing the
reservoir of opportunistic pathogens.8 A number of trials have studied the effect of adenoidectomy alone
or of grommets with adjuvant adenoidectomy in children with OM.9–25 Differences in the study design,
population characteristics, outcomes measured and duration of follow-up, and particularly the use of small
sample sizes, have made it difﬁcult to come to any deﬁnite conclusions about the effects of
adenoidectomy. It is possible – indeed likely – that both over- and undertreatment occurs. An individual
patient data (IPD) meta-analysis, that is, a meta-analysis of the original individual data from previous trials,
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offers a unique opportunity to identify subgroups that may be more or less likely to beneﬁt from
adenoidectomy than others. Members of our group have successfully applied the IPD meta-analysis
methodology to evaluate the effectiveness of antibiotics in children with acute OM and grommets in OME
in speciﬁc subgroups.26,27
Aims and objectives
In this IPD meta-analysis we therefore (1) developed a model to predict the risk of children referred for
adenoidectomy having a prolonged duration of their otitis media. Then, (2a) having evaluated the overall
effect of adenoidectomy, with or without grommets, on OM using these IPD, we (2b) identiﬁed those
subgroups of children who beneﬁt most, or who are most likely to beneﬁt, from adenoidectomy, with or
without grommets.
BACKGROUND AND INTRODUCTION
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Chapter 2 Methods of research
Protocol and registration
The original protocol for this IPD meta-analysis was published on the website of the Health Technology
Assessment programme of the National Institute for Health Research (see www.hta.ac.uk/2576). The
protocol is included in this report (see Appendix 1). The study was also registered on 13 September 2011
in the PROSPERO register with the number CRD42011001549 (see www.crd.york.ac.uk/PROSPERO/
display_record.asp?ID=CRD42011001549).
As in any IPD meta-analysis, small but potentially important changes to intentions have to be made on the
basis of the speciﬁc data that are made available to the research team. In this regard, discussion with the
principal investigators and/or study representatives included in the IPD meta-analysis took place at two
meetings (Amsterdam, the Netherlands, 21 May 2012, and Oxford, UK, 3 September 2012). This led to
the decision to promote to the primary outcome a composite outcome measure that was already included
in the protocol as a secondary outcome, because the primary outcome originally proposed could not be
determined in a signiﬁcant proportion of studies, severely limiting the value of any ensuing meta-analysis.
Speciﬁcally, number of OM episodes was replaced by failure at 12 months. By using such a composite end
point we were able to aggregate our data and generalise results. This was critical to accomplish our aim of
establishing which children beneﬁt more or less from adenoidectomy.
An overview of the adaptations to the study protocol and the reasons for them can be found in
Appendix 2.
Selection of the trials and quality assessment
For this IPD meta-analysis the same search strategy was used as in our Cochrane review.28 We searched
the following databases from their inception: the Cochrane Ear, Nose and Throat Disorders Group Trials
Register, the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library Issue 1,
2009), PubMed, EMBASE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Latin
American and Caribbean Health Sciences Literature (LILACS), KoreaMed, IndMED, PakMediNet, CAB
Abstracts, Web of Science, BIOSIS Previews, China National Knowledge Infrastructure (CNKI), the
metaRegister of Current Controlled Trials (mRCT), ClinicalTrials.gov, the International Clinical Trials Registry
Platform (ICTRP), ClinicalStudyResults.org and Google. We used the following keywords with their
synonyms: ‘adenoidectomy’ and ‘otitis’ (see Appendix 3 for the complete search strategy). We checked the
bibliography of all relevant studies and reviews to identify supplemental studies. Unpublished studies were
also eligible for inclusion. We imposed no language restriction on the searches. The date of the last search
for the Cochrane review was 30 March 2009. Thereafter, we received weekly updates from PubMed and
performed a full updated search on 7 June 2012 (including CENTRAL, The Cochrane Library Issue 5, 2012).
The ﬁnal selection of eligible studies and the quality assessment were carried out by two of the authors of
the Cochrane review (CB and MvdA) and disagreement was resolved by discussion.
For the quality assessment we used The Cochrane Collaboration quality assessment (risk of bias) tool,29
which requires a judgement on sequence generation, allocation concealment (whether or not assignment
to the intervention or control group could be foreseen by the participants or the investigators), blinding,
incomplete outcome data, selective outcome reporting and evaluation of other possible biases. The
judgement on the risk of bias for this IPD meta-analysis may differ from the judgement in the Cochrane
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review because for this IPD meta-analysis we obtained the original raw data sets from the primary
investigators of all of the included trials and we did not have to rely on the published information alone.
We checked and reanalysed all data sets to see if it was possible to recalculate the published results. When
needed, we contacted the principal investigators to resolve any questions. The two data sets that were
provided in Finnish16,17 were translated into English by one of the project members (CB). The dictionary
developed during the translation of the ﬁrst data set16 was approved by the principal investigator and was
then used to translate the second dataset.17 After checking the quality of the data sets we developed one
overall data set by recoding the variables from the individual data sets to the set of variables used for the
IPD meta-analysis. For season, we used country-speciﬁc seasons, that is, June could be either spring or
summer, depending on the country in which the study was performed. We used date of surgery to
calculate the season and winter/spring was used in the analyses as the measure for seasonality. For
children in the non-surgical group we used the date of enrolment.
Types of studies and patients
Studies were eligible for inclusion in this IPD meta-analysis if they were a randomised controlled trial (RCT)
in children up to 12 years of age diagnosed with OM (being recurrent AOM and/or persistent OME) in
which adenoidectomy (with or without grommets) was compared with non-surgical treatment or
grommets. Trials in which all children underwent adenoidectomy were therefore not eligible. We included
trials in which the method of randomisation was not speciﬁed in detail, but we excluded quasi-randomised
trials (e.g. allocation by date of birth or record number). Studies had to have a follow-up period of at least
1 year. Desirable time points for outcome assessment were 6, 12, 18 and 24 months.
Types of interventions
Interventions
Four interventions or intervention combinations were evaluated:
1. adenoidectomy alone
2. adenoidectomy with myringotomy
3. adenoidectomy with unilateral grommet
4. adenoidectomy with bilateral grommets.
However, these were grouped together in two intervention ‘bundles’:
1. adenoidectomy with unilateral or bilateral grommets
2. adenoidectomy with or without myringotomy.
Comparator
The comparators evaluated were:
1. unilateral or bilateral grommets
2. non-surgical treatment or myringotomy alone.
To evaluate the effects of adenoidectomy we compared the following interventions:
l main comparison (Figure 1a):
¢ adenoidectomy with or without grommets compared with non-surgical treatment or grommets
only (this comparison was selected on the basis of prior knowledge of the available data sets
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included in our conventional meta-analysis and was chosen to maximise the statistical power to
identify subgroups).
l other comparisons (Figure 1b):
¢ adenoidectomy with unilateral or bilateral grommets compared with non-surgical treatment
¢ adenoidectomy with unilateral or bilateral grommets compared with unilateral or bilateral
grommets
¢ adenoidectomy without grommets compared with non-surgical treatment
¢ adenoidectomy without grommets compared with unilateral or bilateral grommets.
We did not compare the following interventions as these analyses do not fulﬁl the criteria for inclusion in
this IPD meta-analysis:
l adenoidectomy with unilateral or bilateral grommets compared with adenoidectomy without grommets
l unilateral or bilateral grommets compared with non-surgical treatment.
Types of outcome measures
Primary outcome
The primary outcome is failure at 12 months, which was deﬁned as one or more of the following
components:
1. four or more AOM episodes (including episodes of otorrhoea) per year
2. presence of effusion for ≥ 50% of the time
3. need for additional surgery
4. hearing* improved by < 10 dB.
*Hearing was expressed as a mean air conduction hearing level measured by age-appropriate audiometry
(if possible averaged over 500, 1000, 2000 and 4000 Hz). In all children the binaural average was taken.
This includes trials that used unilateral grommets and randomised ears rather than children.
Not all components were recorded in each study and the number of children failing on each of these
components by treatment group and study varied (see Appendix 10).
Adenoidectomy
Adenoidectomy with
uni- or bilateral
grommets
Uni- or bilateral
grommets
Non-surgical
treatment
(a)
Adenoidectomy
Adenoidectomy with
uni- or bilateral
grommets
Uni- or bilateral
grommets
Non-surgical
treatment
(b)
FIGURE 1 (a) Main comparison: adenoidectomy with or without grommets compared with non-surgical treatment
or grommets only; and (b) other comparisons.
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In the original protocol this composite outcome was included as a secondary outcome. The primary
outcome was number of OM episodes. When we were analysing the available data sets we realised that
data on the original primary outcome were incomplete as the deﬁnition and evaluation of outcomes varied
considerably across the trials. We followed the recommended conventions for IPD meta-analysis and,
rather than presenting an ‘empty’ review of little utility, we sought to develop – through consensus with
clinicians, including the original triallists – a composite primary outcome that allowed inclusion of all of the
trials, the aim being to make maximum use of the available information to develop a robust answer to the
clinical questions posed. We emphasise to readers who may be unfamiliar with this speciﬁc type of
secondary research that redeﬁning a primary outcome in this way is not unusual and not the same as
changing outcomes in primary research.
Secondary outcomes
1. All individual items of failure at 12 months:
¢ four or more AOM episodes (including episodes of otorrhoea) per year
¢ presence of effusion for ≥ 50% of the time (i.e. effusion for > 6 months)
¢ need for additional surgery
¢ hearing improved by < 10 dB.
2. Number of episodes of AOM during follow-up – in the ﬁrst 6, 12, 18 and 24 months.
3. Time with effusion during follow-up measured in number of weeks – in the ﬁrst 6, 12, 18
and 24 months.
4. Additional surgery during follow-up – in the ﬁrst 6, 18 and 24 months.
5. Average hearing loss measured in dBHL (hearing level in decibels as assessed on an audiometer) –
after 6, 12, 18 and 24 months’ follow-up.
6. Improvement in hearing level < 10 dB – after 6, 18 and 24 months’ follow-up.
7. Adverse effects and events (including morbidity of surgery).
Statistical analysis
1. Development of a model to predict the risk of children referred for
adenoidectomy having a prolonged duration of their otitis media
To address this objective we examined the association between each potential predictor (subgrouping
variable) and the primary outcome of failure at 12 months by univariate logistic regression analysis. The a
priori-deﬁned potential predictors were based on clinical reasoning, knowledge of the literature (including
the analysed studies) and discussion with experts. They are:
l age
l sex
l season (winter vs. summer)
l day-care attendance
l passive smoking
l breastfeeding
l pneumococcal vaccination status
l atopy or allergy
l number of previous episodes of upper respiratory tract infection
l number of previous episodes of AOM
l occurrence of one or more episodes of AOM in the previous year
l age at onset
l duration of symptoms
l middle ear impedance (tympanometric ﬁndings)
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l baseline hearing level
l indication for surgery (recurrent AOM or persistent OME)
l presence of OME at study entry.
Only patients in the non-surgical group of the available RCTs were selected for the prognostic study, that
is, children referred for adenoidectomy but randomised to the non-surgical group. This is appropriate
because adenoidectomy with or without grommets might inﬂuence the course of the disease and might
result in an invalid natural history model. Predictors that were univariately associated with the outcome
(p < 0.10) were included in multivariate logistic regression analyses. The models were compacted by
excluding predictors from the model with a p-value of > 0.05. The ability of the models to discriminate
between children who will or will not experience failure at 12 months was estimated by the area under
the receiver operating curve (ROC). The ROC area is a suitable parameter to summarise discriminative or
predictive values and can range from 0.5 (no discrimination, like a coin ﬂip) to 1.0 (perfect discrimination).
In addition, we calculated the absolute risks of failure at 12 months using the predictors that were
identiﬁed in the multivariate analyses and combinations of those predictors.
We also performed two sensitivity analyses. In the ﬁrst we sought to determine whether the indication for
adenoidectomy (recurrent AOM or persistent OME) resulted in different prognostic factors from those that
were found for the total group. In the second sensitivity analysis we used an alternative set of deﬁnitions
of failure at 12 months as the outcome.
2a. Evaluation of the overall effect of adenoidectomy, with or without
grommets, on otitis media using these individual patient data
We quantiﬁed the overall effect of the interventions for all comparisons listed above (see also Figure 1a
and b). We used Review Manager (RevMan) version 5.2 (The Cochrane Collaboration, The Nordic
Cochrane Centre, Copenhagen, Denmark) to create forest plots presenting both rate differences (RDs) and
rate ratios (RRs) for the main effects. We also calculated RRs, RDs, number needed to treat (NNT) and 95%
conﬁdence intervals (CIs) for each of these using regression analysis.
We were unable to calculate adjusted RDs because of the calculation artefact, which occurs when there
are zero events in a study (in this case that of Nguyen et al.21). Therefore, we calculated unadjusted RDs
with a binominal model using an identity link:
YðfailureÞ ¼ αþ β  intervention ð1Þ
To adjust for a potential study effect we also performed a Poisson regression analysis with robust standard
errors, which enabled us to calculate an adjusted RR:
LogðfailureÞ ¼ αþ β  intervention þ β  dummy study ð2Þ
For continuous outcomes we calculated adjusted mean differences:
YðfailureÞ ¼ αþ β  intervention þ β  dummy study ð3Þ
2b. Identification of those subgroups of children who benefit most, or who
are most likely to benefit, from adenoidectomy with or without grommets
To assess whether the effect of the intervention under study was modiﬁed by the identiﬁed prognostic
factors, we performed an analysis using a binominal model with an identity link, including an
interaction effect:
YðfailureÞ ¼ αþ β  intervention  subgrouping variable ð4Þ
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To adjust for study and the subgrouping variable(s) we also performed a Poisson regression analysis with
robust standard errors including both interaction terms and potential confounders (i.e. study and age) to
calculate adjusted RRs and their 95% CIs.
We used the Wald statistic from the adjusted Poisson regression to study the signiﬁcance of the
interaction term:
LogðfailureÞ ¼ αþ β  interventionþ β  subgrouping variableðsÞ þ β  dummy studyþ β
 intervention  subgrouping variableðsÞ ð5Þ
For continuous outcomes we calculated an adjusted mean difference:
YðfailureÞ ¼ αþ β  intervention þ β  subgrouping variableðsÞ þ β  dummy studyþ β
 intervention  subgrouping variableðsÞ ð6Þ
We will present subgroup effects only for those variables that showed a signiﬁcant interaction effect
(p≤ 0.1) and for subgroups with sufﬁcient numbers (n> 15) to present stratiﬁed results. We used our
clinical experience and reasoning and decided a priori to include age and indication as potential subgroup
variables. Furthermore, we decided to examine subgroup effects in the two distinct populations deﬁned by
the indication for surgery – recurrent AOM compared with persistent OME.
As many of the subgroup comparisons are between studies rather than within study, we will not present
forest plots for the subgrouping variables but tables with the RDs, RRs and adjusted RRs from the
regression analyses.
We decided not to impute missing data because of the low number of missing data points within the
included trials. Furthermore, we decided not to impute data across trials in situations in which a variable
was completely missing from a trial. We found in an earlier study30 that imputation of missing data across
trials might lead to bias, as association of covariates might differ across the included studies.
In addition to the intention-to-treat analysis, we also performed three sensitivity analyses to assess the
robustness of our ﬁndings. In the ﬁrst we performed a per-protocol analysis in which we excluded the
children who did not follow the protocol to which they were randomised. The second was an as-treated
analysis in which we analysed the children according to the treatment that they received. In the third we
used an alternative set of deﬁnitions of failure at 12 months as the outcome. We performed all sensitivity
analyses only for the primary outcome of the main comparison.
All analyses were performed with IBM SPSS Statistics version 20.0 (IBM Corp., Armonk, NY, USA)
and Rothman’s Episheet (11 June 2008; Spreadsheets for the Analysis of Epidemiologic Data,
see http://krothman.hostbyet2.com/Episheet.xls).
Medical ethical approval
The study team discussed the project with the Medical Ethical Committee of the University Medical Center
Utrecht. The committee conﬁrmed that ethical approval was not required as the study uses only
anonymous data from previously performed studies for which both informed consent and ethical approval
had already been obtained.
METHODS OF RESEARCH
8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Chapter 3 Results
Searches
Our searches (2009 and 2012) retrieved a total of 503 articles (Figure 2). We ﬁrst screened the articles by
title/abstract and excluded ﬁve trials in which all children underwent adenoidectomy.31–35 An additional
467 studies were excluded for other reasons, for example follow-up for <12 months. In total, 31 articles
were eligible for further assessment. One study by Sagnelli et al.36 could not be retrieved. We excluded
three articles,37–39 describing two trials, because of inadequate randomisation or concealment of allocation.
One article40 was excluded because it was found to report a non-RCT. Furthermore, we identiﬁed 11 of
the publications9,41–50 as providing the same data as more recent articles included in this meta-analysis.
Publications focused on adenotonsillectomy were also excluded except for those in which a separate
analysis for adenoidectomy was undertaken.19,22 No additional trials were identiﬁed from checking the
bibliographies of the selected trials and reviews, nor by contacting the ﬁrst or corresponding author of the
eligible trials.
In total, 15 trials10–25,51,52 were eligible for inclusion in this IPD meta-analysis. We contacted the principal
investigators of these trials to ask if they were willing and able to provide their raw data. We were unable
to contact the principal investigator of one trial.24 The data for four older trials (1978–99) were no longer
available.14,22,23,25 For one trial, additional follow-up data were available.15,51 For another study, additional
unpublished data were also provided.20 Three older studies (1986–90) used a unilateral grommet,10,12,52
whereas the others used no grommets16 or bilateral grommets.11,15,17,18,20,21
Characteristics of included studies
The characteristics of the included studies are shown in Table 1. The inclusion and exclusion criteria are
shown in Appendix 5, the indication for surgery and the age ranges within studies are shown in Appendix
6 and the deﬁnitions of recurrent AOM and persistent OME used in the included studies are shown in
Appendix 7.
We included raw data from 10 trials,10–12,15–21,51,52 including 1761 children. The trials were published
between 1990 and 2012. Eight trials were undertaken in Europe (four in Finland15–18 and four in the
UK10,12,20,52), one in the USA11 and one in Canada.21
Speciﬁc differences between included studies
The 10 trials differed in a number of ways but the most important were in terms of indication for surgery,
interventions studied and frequency of outcome assessment.
Indications
l Recurrent AOM: three trials16–18 included children with recurrent AOM.
l Persistent OME: ﬁve trials10–12,20,52 included children with persistent OME.
l Both recurrent AOM and persistent OME: two trials15,21 included children with both recurrent AOM and
persistent OME.
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Interventions
For analysis we divided the trials into two groups based on the surgical interventions being ‘bundled’
together as described earlier:
l adenoidectomy with unilateral or bilateral grommet(s): there are nine trials10–12,15,17,18,20,21,52 in
this group
l adenoidectomy with or without myringotomy: there are two trials11,16 in this group; one trial11 included
both adenoidectomy with grommets and adenoidectomy with myringotomy.
Frequency of outcome assessment
Trials varied in both the frequency with which outcomes were assessed and the way in which outcomes
were assessed. Some examined participants at 6-month intervals,10,12,15,20,52 whereas others used diaries or
more frequent visits11,16–18,21 to record outcomes.
Methodological quality of the included studies
The results of the risk of bias assessment are presented in Table 2. We classiﬁed the risk of selection bias
because of inadequate sequence generation as low for eight10–12,15–17,20,52 out of 10 studies and unclear in
two studies.18,21 We classiﬁed the risk of selection bias because of inadequate allocation concealment as
unclear in three studies11,18,21 and as low in the remaining seven studies.10,12,15–17,20,52 The risk of
performance bias (blinding of participants and personnel) and detection bias (blinding of outcome
assessment) was unclear in seven studies10,11,15–18,21 and six studies11,15–18,21 respectively. Incomplete
Records identified through database searching and other sources
(n = 503)
Records excluded (n = 472)
– all children had undergone adenoidectomy (n = 5)
– other reasons (e.g. no RCT, follow-up < 12 months; n = 467)
Publications excluded (n = 16)
– full texts could not be retrieved (n = 1)
– non-randomised controlled study (n = 1)
– inadequate randomisation/concealment (n = 3; on two studies)
– same data presented in more recent publications (n = 11)
Studies excluded (k = 5)
– not able to contact the principal investigator (k = 1)
– principal investigator willing to participate, but data no longer 
  available (k = 4)
Full text assessed for eligibility
(n = 31)
Studies eligible for inclusion
(k = 15)
Studies included in the IPD meta-analysis
(k = 10, including 1.761 children)
FIGURE 2 Flow chart for adenoidectomy studies. n, number of publications (there could be more than one
publication per study); k, number of studies.
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outcome data may have caused attrition bias in ﬁve studies10,12,16,20,52 and is likely to have caused bias in
two studies.18,21 As the full data sets were provided, the risk of reporting bias because of selective
reporting is low in all studies. We classiﬁed one study21 as having a high risk of other bias. In this study the
randomisation did not result in two similar groups. Age and degree of adenoid hypertrophy differed
between the two groups. Furthermore, the follow-up data were obtained by questionnaires completed
retrospectively at 6-monthly intervals. This could have led to recall bias. The risk of other bias was classiﬁed
as unclear for ﬁve studies10–12,18,52,53 and low for the remaining four studies.15–17,20
Overall we concluded that eight studies10–12,15–17,20,52 were at a low risk of bias and two18,21 were at
a moderate risk of bias.
Note that the judgement of the risk of bias for selective reporting differs from the judgement in the
Cochrane review28 because in this IPD meta-analysis the complete data sets were obtained and we did not
have to rely on the publications alone, resulting in low risk for selective reporting in all studies. Also,
the judgement on blinding is now divided into blinding of participants and personnel, and blinding of
outcome assessment.
Characteristics of participants at baseline
All participants
The characteristics of all 1761 children are recorded in the ﬁnal column of Table 3. Important
characteristics to note are:
l Age. The overall proportion of children aged < 2 years is 43% and most of these children had
recurrent AOM. Some studies included no children aged < 2 years. Also, note that 42% of children
were aged > 4 years.
l Indication. Just over half of the children (54.3%) were offered surgery for persistent OME.
l Pneumococcal vaccination. Most children (78.9%) were in the ‘not vaccinated’ group because the
trials were performed in the era before the introduction of the vaccination.
l Hearing loss. The average hearing loss was 31.9 dBHL (range 13.1–65 dBHL) but this average is based
on 590 participants as hearing loss was not measured in all studies.
l Type of grommets. No study included ‘long-term’ grommets.
TABLE 3 Characteristics of participants at baseline
Characteristic
Adenoidectomy with
or without unilateral
or bilateral grommets
(n = 767, k = 10), n (%)
Non-surgical treatment
or unilateral or bilateral
grommets only
(n = 994, k = 10), n (%)
Total (n = 1761,
k = 10), n (%)
Age (years), mean (SD), range 3.6 (2.2), (0.7–9.7) 3.3 (2.1), (0.5–9.8) 3.4 (2.2), (0.5–9.8)
< 2 years 302 (39.4) 449 (45.2) 751 (42.6)
< 4 years 442 (57.6) 575 (57.8) 1017 (57.8)
Sex: male 435 (56.7) 550 (55.3) 985 (55.9)
Indication
Recurrent AOM 317 (41.3) 466 (46.9) 783 (44.5)
Persistent OME 442 (57.6) 514 (51.7) 956 (54.3)
Both 8 (1.0) 12 (1.2) 20 (1.1)
continued
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TABLE 3 Characteristics of participants at baseline (continued )
Characteristic
Adenoidectomy with
or without unilateral
or bilateral grommets
(n = 767, k = 10), n (%)
Non-surgical treatment
or unilateral or bilateral
grommets only
(n = 994, k = 10), n (%)
Total (n = 1761,
k = 10), n (%)
Grommets
No grommets 95 (12.4) 343 (34.5) 438 (24.9)
Unilateral 195 (25.4) 195 (19.6) 390 (22.1)
Bilateral 477 (62.2) 456 (45.9) 933 (53.0)
Type of grommets
Shepard 286 (42.6) 286 (43.9) 572 (43.2)
Shah 37 (5.5) 35 (5.4) 72 (5.4)
Donaldsona 284 (42.3) 262 (40.2) 546 (41.3)
Reuter Bobbin 33 (4.9) 37 (5.7) 70 (5.3)
Armstrong 32 (4.8) 31 (4.8) 63 (4.8)
Season at time of surgery
Winter/spring 441 (61.1) 548 (57.8) 989 (56.2)
Siblings: yes 446 (81.7) 556 (79.3) 1002 (80.4)
Passive smoking: yes 379 (47.0) 364 (45.7) 643 (36.5)
Day-care attendance
Yes 233 (53.1) 310 (53.3) 543 (53.2)
Not relevant (child too old) 197 (31.0) 271 (31.8) 468 (31.4)
Pneumococcal vaccination
Yes 47 (12.1) 40 (5.0) 87 (6.0)
Trial performed before
vaccination was available
533 (80.0) 618 (77.9) 1151 (78.9)
Number of AOM episodes in past
0 125 (18.4) 137 (15.2) 262 (16.6)
1–3 episodes 193 (28.3) 250 (27.7) 443 (28.0)
≥ 4 363 (53.3) 514 (57.0) 877 (55.4)
OME present at study entry
Yes – unilateral 95 (14.1) 63 (6.9) 158 (10.0)
Yes – bilateral 331 (49.3) 440 (48.2) 771 (48.6)
No 246 (36.6) 410 (44.9) 656 (41.4)
Hearing loss (dB), mean (SD), range 31.4 (7.3), (13.1–65.0) 32.2 (6.7), (13.8–50.0) 31.9 (6.9), (13.1–65.0)
< 25 dBHL 45 (19.2) 47 (13.2) 92 (15.6)
≥ 25 dBHL 189 (80.8) 309 (86.8) 498 (84.4)
k, number of studies; n, number of children; SD, standard deviation.
a In the Mattila et al. trial18 no instruction was provided for the surgeons regarding the preferred type of grommets;
in most cases Donaldson silicone grommets will have been used as they are most commonly used in Finland.
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Participants according to the groups used in the main comparison
Table 3 also presents the characteristics of the participants according to the groups used in the main
comparison. No important differences were seen between the groups.
1. Development of a model to predict the risk of children
referred for adenoidectomy having a prolonged duration
of their otitis media
To determine the predictive factors for failure at 12 months in children referred for adenoidectomy but
randomised to a non-surgical treatment we studied the following factors: age, sex, indication, season,
day-care attendance, breastfeeding, passive smoking, atopy or allergy, number of previous AOM episodes
(less than four vs. four or more), the occurrence of one or more episodes of AOM in the previous year, age
at ﬁrst occurrence of AOM, baseline hearing level, duration of symptoms, and OME at study entry. We
could not include pneumococcal vaccination status as this was not reported in any of the studies included
in this analysis.
Univariate analysis
The results of the univariate analysis are shown in Table 4. The results are in the form of odds ratios (ORs)
and 95% CIs.
TABLE 4 Univariate analysis for the primary outcome of failure at 12 months
Prognostic factor
Non-surgical groupa (n = 343, k = 3)
OR (95% CI)b p-valueb
Indication: persistent OME 13.68 (7.24 to 25.83) < 0.0001
Sex 0.99 (0.65 to 1.52) 0.973
Age < 2 years 12.61 (6.79 to 23.42) < 0.0001
Age < 4 years 10.87 (5.76 to 20.51) < 0.0001
Season (winter/spring vs. summer/autumn) 1.32 (0.85 to 20.06) 0.212
Day-care attendance 2.12 (1.28 to 3.53) 0.004
Breastfeeding 1.02 (0.66 to 1.57) 0.941
Passive smoking 0.88 (0.57 to 1.37) 0.574
Atopy or allergy 2.23 (0.88 to 5.67) 0.091
AOM in the past yes/no 0.08 (0.02 to 0.26) < 0.0001
AOM in the past less than/more than four episodes 0.18 (0.11 to 0.31) < 0.0001
URTI in the past less than/more than four episodes 0.62 (0.16 to 2.50) 0.623
Age at ﬁrst AOM (</> 1 year) 0.39 (0.22 to 0.71) 0.002
Baseline hearing level (</> 25 dB) 1.05 (0.12 to 9.15) 0.963
Duration of symptoms (</> 6 months) 0.78 (0.09 to 6.60) 0.816
OME at study entry 13.23 (7.19 to 24.35) < 0.0001
URTI, upper respiratory tract infection.
a MRC Multicentre Otitis Media Study Group,20 Koivunen et al.16 and Kujala et al.17
b Bold text indicates values that are statistically signiﬁcant.
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Univariate predictors of failure at 12 months were:
l indication
l age
l AOM in the past
l day-care attendance
l age at ﬁrst AOM
l OME at study entry.
Multivariate analysis
Table 5 shows the independent predictors of failing to improve at 12 months. The only remaining
independent predictor of failure at 12 months (when those that are not statistically signiﬁcant are
removed) was indication (OR 19.8, 95% CI 9.7 to 40.6). The prognostic model had an area under the
curve of 0.77 (95% CI 0.72 to 0.82).
Absolute risks
The absolute risk for the whole group of failing to improve at 12 months was 56% (193 of the 343
children). The absolute risk of failing to improve was highest for children with the indication persistent
OME (absolute risk 0.89, 95% CI 0.84 to 0.95, 36% of all children). The absolute risk for children with the
indication recurrent AOM was 0.38 (95% CI 0.32 to 0.44, 64% of all children).
Sensitivity analyses
Sensitivity analyses using several alternative deﬁnitions of failure at 12 months gave similar results for both
the univariate and the multivariate analyses.
2a. Evaluation of the overall effect of adenoidectomy, with or
without grommets on otitis media using individual
patient data
Main comparison: adenoidectomy with or without grommets compared
with non-surgical treatment or grommets only
Primary outcome
Figure 3 provides an overview of the overall effect within each individual study.
In total, the proportion of children who failed at 12 months in the adenoidectomy group (adenoidectomy
with or without grommets) was 31.9% whereas the proportion of children who failed at 12 months in the
no adenoidectomy (non-surgical or grommets alone) group was 44.7%. The RD for failure at 12 months
was −12.7% (95% CI −17.3% to −8.2%), resulting in a NNT of eight children to prevent one failure.
The RR was 0.72 (95% CI 0.63 to 0.81) and the adjusted RR (using a dummy for study) was 0.76 (95% CI
0.69 to 0.85) (Table 6).
TABLE 5 Multivariate analysis for predicting failure at 12 months
Model
No. of
patients
Overall % of patients
with outcome at
12 months
correctly predicted
Area under the
ROC curve (95% CI)
Remaining factor
OR (95% CI)
Non-surgical group 343 71.7 0.77 (0.72 to 0.82) Indication: 19.8 (9.7 to 40.6)
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In this analysis the proportion of children without grommets, with a unilateral grommet and with bilateral
grommets differed between the groups. In the adenoidectomy group 12% did not have grommets, 25%
had a unilateral grommet and 62% had bilateral grommets. In the no adenoidectomy group these
percentages were 35%, 20% and 46% respectively (see Table 3). To study whether this imbalance
inﬂuenced our results we performed sensitivity analyses by omitting one group at a time (i.e. no
grommets, unilateral grommets or bilateral grommets). The results of the sensitivity analyses did not differ
and therefore the imbalance did not affect the outcome.
Secondary outcomes
Data on all available secondary outcomes are also presented in Table 6.
For all secondary outcomes, results in children in the adenoidectomy group were statistically signiﬁcantly
better than results in those in the no adenoidectomy group. During follow-up, children in the
adenoidectomy group had a lower number of AOM episodes, less time with effusion, less additional
surgery, less hearing loss and improved hearing levels at 6, 12, 18 and 24 months’ follow-up. The clinical
importance of these ﬁndings is not clear. The reductions in both time with effusion and number of AOM
episodes are very modest. However, about one in ﬁve children avoid the need for additional surgery.
The clinical importance of an average 4-dB improvement in hearing loss has been debated and we
consider it further below.
Secondary comparisons
Adenoidectomy with unilateral or bilateral grommets compared with
non-surgical treatment
Primary outcome
Figure 4 provides an overview of the overall effect within each individual study.
The proportion of children who failed at 12 months was 32.4% in the group in which all children had
adenoidectomy with a grommet in one ear or both and 56.3% in the non-surgical group. The RD for
failure at 12 months was −23.8% (95% CI −30.2% to −17.5%), resulting in a NNT of ﬁve children to
prevent one failure. The RR was 0.58 (0.50 to 0.67) and the adjusted RR (using a dummy for study) was
0.48 (0.40 to 0.59) (Table 7).
Secondary outcomes
Data on all available secondary outcomes are also presented in Table 7.
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Adenoidectomy with unilateral or bilateral grommets compared with
unilateral or bilateral grommets
Primary outcome
Figure 5 provides an overview of the overall effect within each individual study. The proportion of children
who failed at 12 months was 32.4% in the group in which all children had adenoidectomy with a
grommet in one or both ears and 38.6% in the group of children who had grommets only in one or
both ears. The RD for failure at 12 months was −6.2% (95% CI −11.3% to −1.0%), resulting in a NNT of
17 children to prevent one failure. The RR was 0.84 (95% CI 0.73 to 0.97) and the adjusted RR (using a
dummy for study) was 0.86 (95% CI 0.76 to 0.97) (Table 8).
The proportions of unilateral and bilateral tubes were similar in both groups. In the adenoidectomy with
grommets group 29% had a unilateral grommet and 71% had bilateral grommets whereas in the
grommets only group the proportions were 30% and 70% respectively. It is therefore unlikely that the
results are inﬂuenced by the proportion of unilateral or bilateral tubes within each group.
Secondary outcomes
Data on all available secondary outcomes are also presented in Table 8.
Adenoidectomy without grommets compared with non-surgical treatment
Primary outcome
Figure 6 provides an overview of the overall effect within each individual study. The proportion of children
who failed at 12 months was 28.4% in the group in which all children had adenoidectomy alone and
56.3% in the group of children who had non-surgical treatment. The RD for failure at 12 months was
−27.8% (95% CI −38.3% to −17.4%), resulting in a NNT of four children to prevent one failure. The RR
was 0.51 (95% CI 0.36 to 0.70) and the adjusted RR (using a dummy for study) was 0.74 (95% CI 0.49 to
1.12) (Table 9).
Secondary outcomes
Data on all available secondary outcomes are also presented in Table 9.
A large difference was observed between groups during follow-up in the proportion of children with the
presence of effusion for ≥ 50% of the time. However, this may be due to a measurement artefact
because, as some studies had zero events, it was not possible to calculate an adjusted RR. This adjustment
is particular important for these analyses as, in the studies contributing participants to the adenoidectomy
only group,11,16 children were examined more frequently and more observations were made than in those
studies contributing participants to the non-surgical group.16,17,20
Adenoidectomy without grommets compared with unilateral or
bilateral grommets
Primary outcome
Figure 7 provides an overview of the overall effect within each individual study. The proportion of children
who failed at 12 months was 28.4% in the group in which all children had adenoidectomy alone and
38.6% in the group who had grommets. The RD for failure at 12 months was −10.4% (95% CI −20.0%
to −0.3%), resulting in a NNT of 10 children to prevent one failure. The RR was 0.74 (95% CI 0.53 to
1.03) and the adjusted RR (using a dummy for study) was 2.07 (95% CI 0.58 to 7.31) (Table 10).
Secondary outcomes
Data on all available secondary outcomes are also presented in Table 10. The same large difference
between groups during follow-up in the proportion of children with effusion for ≥ 50% of the time was
noted here, which again may be due to the measurement artefact described in the previous section.
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Sensitivity analysis
A series of sensitivity analyses using alternative deﬁnitions of failure at 12 months showed similar results.
A per-protocol analysis, in which we excluded children in the no adenoidectomy group who nevertheless
underwent adenoidectomy, showed similar results to the intention-to-treat analysis. The as-treated
analysis, in which children from the no adenoidectomy group who had their adenoid removed were
analysed in the adenoidectomy group, was performed with two deﬁnitions of failure.
We had to use another deﬁnition of failure as ‘additional surgery’ was also part of our primary deﬁnition
of failure, resulting in overlapping of the independent and dependent variables. With the main deﬁnition,
that is, including ‘additional surgery’, no effect of adenoidectomy was found, which is probably because of
the overlapping independent and dependent variables. When ‘additional surgery’ was omitted from the
deﬁnition of failure (dependent variable), the signiﬁcant adenoidectomy effect disappeared but the
direction of the effects was similar. The results of the per-protocol and as-treated analyses for the overall
effect are shown in Table 11.
2b. Identiﬁcation of those subgroups of children who beneﬁt most,
or who are most likely to beneﬁt, from adenoidectomy with or
without grommets
The prognostic analyses revealed indication (recurrent AOM or persistent OME) as one potential
subgrouping variable and, in addition, we had decided a priori to include age. We studied these factors
individually and in combination.
All signiﬁcant interaction effects (for both primary and secondary outcomes) for all comparisons are
presented in Appendices 11–15. In the text and ﬁgures that follow we report only signiﬁcant interaction
effects for the analyses stratiﬁed on indication.
Subgroup analysis: main comparison
Adenoidectomy with or without grommets compared with non-surgical
treatment or grommets only
Primary outcome
We found the anticipated differences in effects based on the indication for surgery (recurrent AOM
compared with persistent OME) (Table 12).
l Indication: recurrent AOM – a signiﬁcant interaction effect (p = 0.04) was found for age: < 2 years
compared with ≥ 2 years:
¢ < 2 years: the proportion who failed at 12 months was 15.7% in the adenoidectomy group
(adenoidectomy with or without grommets) and 27.4% in the no adenoidectomy (non-surgical or
grommets alone) group (unadjusted RD –11.7%, 95% CI −17.7% to −5.8%; unadjusted RR 0.57,
95% CI 0.42 to 0.78; adjusted RR 0.63, 95% CI 0.47 to 0.85)
¢ ≥ 2 years: the proportion who failed at 12 months was 18.5% in the adenoidectomy group
(adenoidectomy with or without grommets) and 2.5% in the no adenoidectomy (non-surgical or
grommets alone) group (unadjusted RD 15.7%, 95% CI 3.3% to 28.1%; unadjusted RR 7.27,
95% CI 0.95 to 55.6; adjusted RR 4.96, 95% CI 0.69 to 35.5).
l Indication: persistent OME – a marginal signiﬁcant interaction effect (p = 0.1) was found for age:
< 4 years compared with ≥ 4 years:
¢ < 4 years: the proportion who failed at 12 months was 23.4% in the adenoidectomy group
(adenoidectomy with or without grommets) and 29.7% in the no adenoidectomy (non-surgical or
DOI: 10.3310/hta18050 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 5
41
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Boonacker et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
TA
B
LE
11
A
s-
tr
ea
te
d
an
d
p
er
-p
ro
to
co
la
n
al
ys
es
fo
r
th
e
o
ve
ra
ll
ef
fe
ct
o
f
ad
en
o
id
ec
to
m
y
w
it
h
o
r
w
it
h
o
u
t
g
ro
m
m
et
s
co
m
p
ar
ed
w
it
h
n
o
n
-s
u
rg
ic
al
tr
ea
tm
en
t
o
r
g
ro
m
m
et
s
o
n
ly
(n
=
17
61
)
A
n
al
ys
is
A
d
en
o
id
ec
to
m
y
w
it
h
o
r
w
it
h
o
u
t
u
n
ila
te
ra
lo
r
b
ila
te
ra
lg
ro
m
m
et
s,
n
/N
(%
)
N
o
n
-s
u
rg
ic
al
tr
ea
tm
en
t
o
r
u
n
ila
te
ra
lo
r
b
ila
te
ra
lg
ro
m
m
et
s
o
n
ly
,n
/N
(%
)
R
D
(9
5%
C
I)
a
N
N
Ta
R
R
(9
5%
C
I)
a
A
d
ju
st
ed
R
R
(9
5%
C
I)
a
In
te
nt
io
n
to
tr
ea
t
24
5/
76
7
(3
1.
9)
44
4/
99
4
(4
4.
7)
−
12
.7
%
(−
17
.2
%
to
−
8.
2%
)
8
0.
72
(0
.6
3
to
0.
81
)
0.
76
(0
.6
9
to
0.
85
)
Pe
r
pr
ot
oc
ol
24
5/
76
7
(3
1.
9)
35
5/
90
5
(3
9.
2)
−
7.
3%
(−
11
.9
%
to
−
2.
7%
)
10
0.
81
(0
.7
1
to
0.
93
)
0.
88
(0
.7
8
to
0.
98
)
A
s
tr
ea
te
db
33
4/
85
6
(3
9.
0)
35
5/
90
5
(3
9.
2)
−
0.
2%
(−
4.
8%
to
4.
4%
)
–
1.
00
(0
.8
9
to
1.
12
)
1.
08
(0
.9
8
to
1.
20
)
A
s
tr
ea
te
dc
27
0/
85
6
(3
1.
5)
32
4/
90
5
(3
5.
8)
−
4.
3%
(−
8.
7%
to
0.
2%
)
–
0.
88
(0
.7
7
to
1.
01
)
0.
97
(0
.8
7
to
1.
08
)
n
,
nu
m
be
r
of
ch
ild
re
n.
a
Bo
ld
te
xt
in
di
ca
te
s
va
lu
es
th
at
ar
e
st
at
is
tic
al
ly
si
gn
iﬁ
ca
nt
.
b
Fa
ilu
re
de
ﬁ
ne
d
as
fo
ur
or
m
or
e
A
O
M
ep
is
od
es
pe
r
ye
ar
,
pr
es
en
ce
of
ef
fu
si
on
fo
r
≥
50
%
of
th
e
tim
e,
ad
di
tio
na
ls
ur
ge
ry
an
d
im
pr
ov
em
en
t
in
he
ar
in
g
le
ve
l<
10
dB
.
c
Fa
ilu
re
de
ﬁ
ne
d
as
fo
ur
or
m
or
e
A
O
M
ep
is
od
es
pe
r
ye
ar
,
pr
es
en
ce
of
ef
fu
si
on
fo
r
≥
50
%
of
th
e
tim
e
an
d
im
pr
ov
em
en
t
in
he
ar
in
g
le
ve
l<
10
dB
.
RESULTS
42
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TA
B
LE
12
Si
g
n
iﬁ
ca
n
t
in
te
ra
ct
io
n
ef
fe
ct
s
fo
r
ad
en
o
id
ec
to
m
y
w
it
h
o
r
w
it
h
o
u
t
g
ro
m
m
et
s
co
m
p
ar
ed
w
it
h
n
o
n
-s
u
rg
ic
al
tr
ea
tm
en
t
o
r
g
ro
m
m
et
s
o
n
ly
:s
tr
at
iﬁ
ed
b
y
in
d
ic
at
io
n
fo
r
su
rg
er
y
n
(%
)
A
d
en
o
id
ec
to
m
y
w
it
h
o
r
w
it
h
o
u
t
u
n
ila
te
ra
l
o
r
b
ila
te
ra
lg
ro
m
m
et
sa
N
o
n
-s
u
rg
ic
al
tr
ea
tm
en
t
o
r
u
n
ila
te
ra
lo
r
b
ila
te
ra
l
g
ro
m
m
et
s
o
n
ly
b
R
D
(9
5%
C
I)
c
N
N
Tc
R
R
o
r
m
ea
n
d
if
fe
re
n
ce
(9
5%
C
I)
c
A
d
ju
st
ed
R
R
o
r
m
ea
n
d
if
fe
re
n
ce
(9
5%
C
I)
c
p
-v
al
u
e
fo
r
in
te
ra
ct
io
n
c
In
d
ic
a
ti
o
n
:
re
cu
rr
e
n
t
A
O
M
Pr
im
ar
y
o
u
tc
o
m
e:
fa
ilu
re
af
te
r
12
m
o
n
th
s,
n
/N
(%
)
<
2
ye
ar
s
71
9
(8
9.
5)
44
/2
81
(1
5.
7)
12
0/
43
8
(2
7.
4)
−
11
.7
%
(−
17
.7
%
to
−
5.
8%
)
9
0.
57
(0
.4
2
to
0.
78
)
0.
63
(0
.4
7
to
0.
85
)
≥
2
ye
ar
s
84
(1
0.
5)
8/
44
(1
8.
2)
1/
40
(2
.5
)
15
.7
%
(3
.3
%
to
28
.1
%
)
–
7.
27
(0
.9
5
to
55
.6
)
4.
96
(0
.6
9
to
35
.5
)
0.
04
Se
co
n
d
ar
y
o
u
tc
o
m
e:
fo
u
r
o
r
m
o
re
A
O
M
ep
is
o
d
es
p
er
ye
ar
,
n
/N
(%
)
<
2
ye
ar
s
65
8
(9
1.
0)
32
/2
52
(1
2.
7)
76
/4
06
(1
8.
7)
−
6.
0%
(−
11
.6
%
to
−
0.
4%
)
17
0.
68
(0
.4
6
to
0.
99
)
0.
71
(0
.4
9
to
1.
02
)
≥
2
ye
ar
s
65
(9
.0
)
7/
33
(2
1.
2)
1/
32
(3
.1
)
18
.1
%
(2
.9
%
to
33
.3
%
)
–
6.
79
(0
.8
8
to
52
.1
0)
4.
80
(0
.6
4
to
35
.7
)
0.
05
Se
co
n
d
ar
y
o
u
tc
o
m
e:
n
u
m
b
er
o
f
A
O
M
ep
is
o
d
es
in
th
e
fi
rs
t
12
m
o
n
th
s
o
f
fo
llo
w
-u
p
,
m
ea
n
(S
D
)
<
2
ye
ar
s
65
8
(9
1.
0)
1.
5
(1
.7
)
2.
0
(2
.1
)
–
–
−
0.
5
(−
0.
8
to
−
0.
2)
−
0.
5
(−
0.
8
to
−
0.
2)
≥
2
ye
ar
s
65
(9
.0
)
1.
6
(2
.0
)
0.
8
(1
.1
)
–
–
0.
8
(0
.0
to
1.
6)
0.
6
(–
0.
1
to
1.
4)
<
0.
01
In
d
ic
a
ti
o
n
:
p
e
rs
is
te
n
t
O
M
E
Pr
im
ar
y
o
u
tc
o
m
e:
fa
ilu
re
af
te
r
12
m
o
n
th
s,
n
/N
(%
)
<
4
ye
ar
s
23
9
(2
4.
5)
30
/1
28
(2
3.
4)
33
/1
11
(2
9.
7)
−
6.
9%
(−
17
.5
%
to
4.
9%
)
15
0.
79
(0
.5
2
to
1.
20
)
0.
98
(0
.6
9
to
1.
38
)
≥
4
ye
ar
s
73
7
(7
5.
5)
16
3/
32
2
(5
0.
6)
28
9/
41
5
(6
9.
6)
−
19
.0
%
(−
26
.1
%
to
−
12
.0
%
)
6
0.
73
(0
.6
4
to
0.
82
)
0.
77
(0
.6
8
to
0.
86
)
0.
10 co
nt
in
ue
d
DOI: 10.3310/hta18050 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 5
43
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Boonacker et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
TA
B
LE
12
Si
g
n
iﬁ
ca
n
t
in
te
ra
ct
io
n
ef
fe
ct
s
fo
r
ad
en
o
id
ec
to
m
y
w
it
h
o
r
w
it
h
o
u
t
g
ro
m
m
et
s
co
m
p
ar
ed
w
it
h
n
o
n
-s
u
rg
ic
al
tr
ea
tm
en
t
o
r
g
ro
m
m
et
s
o
n
ly
:s
tr
at
iﬁ
ed
b
y
in
d
ic
at
io
n
fo
r
su
rg
er
y
(c
o
n
ti
n
u
ed
)
n
(%
)
A
d
en
o
id
ec
to
m
y
w
it
h
o
r
w
it
h
o
u
t
u
n
ila
te
ra
l
o
r
b
ila
te
ra
lg
ro
m
m
et
sa
N
o
n
-s
u
rg
ic
al
tr
ea
tm
en
t
o
r
u
n
ila
te
ra
lo
r
b
ila
te
ra
l
g
ro
m
m
et
s
o
n
ly
b
R
D
(9
5%
C
I)
c
N
N
Tc
R
R
o
r
m
ea
n
d
if
fe
re
n
ce
(9
5%
C
I)
c
A
d
ju
st
ed
R
R
o
r
m
ea
n
d
if
fe
re
n
ce
(9
5%
C
I)
c
p
-v
al
u
e
fo
r
in
te
ra
ct
io
n
c
Se
co
n
d
ar
y
o
u
tc
o
m
e:
su
rg
er
y
d
u
ri
n
g
th
e
fi
rs
t
12
m
o
n
th
s
o
f
fo
llo
w
-u
p
,
n
/N
(%
)
<
4
ye
ar
s
23
8
(2
4.
5)
13
/1
27
(1
0.
2)
11
/1
11
(9
.9
)
0.
3%
(−
7.
3%
to
8.
0%
)
–
1.
03
(0
.4
8
to
2.
21
)
1.
03
(0
.4
6
to
2.
30
)
≥
4
ye
ar
s
73
5
(7
5.
5)
7/
32
0
(2
.2
)
78
/4
15
(1
8.
8)
−
16
.6
%
(−
20
.7
%
to
−
12
.5
%
)
6
0.
12
(0
.0
5
to
0.
25
)
0.
13
(0
.0
6
to
0.
27
)
<
0.
01
Se
co
n
d
ar
y
o
u
tc
o
m
e:
n
u
m
b
er
o
f
A
O
M
ep
is
o
d
es
in
th
e
fi
rs
t
12
m
o
n
th
s
o
f
fo
llo
w
-u
p
,
m
ea
n
(S
D
)
<
4
ye
ar
s
18
9
(3
5.
5)
0.
6
(0
.1
)
0.
8
(0
.1
)
–
–
–
0.
2
(−
0.
5
to
0.
2)
0.
1
(−
0.
1
to
0.
4)
≥
4
ye
ar
s
34
3
(6
4.
5)
1.
0
(0
.2
)
1.
5
(0
.2
)
–
–
−
0.
5
(−
0.
9
to
−
0.
1)
−
0.
4
(−
0.
8
to
0.
0)
0.
05
Se
co
n
d
ar
y
o
u
tc
o
m
e:
ti
m
e
w
it
h
ef
fu
si
o
n
d
u
ri
n
g
th
e
fi
rs
t
12
m
o
n
th
s
o
f
fo
llo
w
-u
p
(w
ee
ks
),
m
ea
n
(S
D
)
<
4
ye
ar
s
15
0
(1
8.
1)
11
.1
(1
.7
)
18
.2
(2
.4
)
–
–
−
7.
1
(−
12
.9
to
−
1.
4)
−
3.
2
(−
6.
4
to
−
0.
1)
≥
4
ye
ar
s
68
1
(8
1.
9)
23
.2
(0
.9
)
30
.1
(0
.9
)
–
–
−
7.
0
(−
9.
4
to
−
4.
6)
−
6.
6
(−
9.
0
to
−
4.
3)
0.
05
n
,
nu
m
be
r
of
ch
ild
re
n;
SD
,
st
an
da
rd
de
vi
at
io
n.
a
In
di
ca
tio
n
re
cu
rr
en
t
A
O
M
:
H
am
m
ar
én
-M
al
m
ie
t
al
.,1
5
K
oi
vu
ne
n
et
al
.,1
6
K
uj
al
a
et
al
.,1
7
M
at
til
a
et
al
.5
1
an
d
N
gu
ye
n
et
al
.;2
1
in
di
ca
tio
n
pe
rs
is
te
nt
O
M
E:
Bl
ac
k
et
al
.,5
2
C
as
se
lb
ra
nt
et
al
.,1
1
D
em
ps
te
r
et
al
.,1
2
H
am
m
ar
én
-M
al
m
ie
t
al
.,1
5
M
aw
an
d
Ba
w
de
n,
1
0
M
aw
an
d
H
er
od
,1
9
M
RC
M
ul
tic
en
tr
e
O
tit
is
M
ed
ia
St
ud
y
G
ro
up
2
0
an
d
N
gu
ye
n
et
al
.2
1
b
In
di
ca
tio
n
re
cu
rr
en
t
A
O
M
:
H
am
m
ar
én
-M
al
m
ie
t
al
.,1
5
K
oi
vu
ne
n
et
al
.,1
6
K
uj
al
a
et
al
.,1
7
M
at
til
a
et
al
.5
1
an
d
N
gu
ye
n
et
al
.;2
1
in
di
ca
tio
n
pe
rs
is
te
nt
O
M
E:
Bl
ac
k,
9
C
as
se
lb
ra
nt
et
al
.,1
1
D
em
ps
te
r
et
al
.,1
2
H
am
m
ar
én
-M
al
m
ie
t
al
.,1
5
M
aw
an
d
Ba
w
de
n,
1
0
M
aw
an
d
H
er
od
,1
9
M
RC
M
ul
tic
en
tr
e
O
tit
is
M
ed
ia
St
ud
y
G
ro
up
2
0
an
d
N
gu
ye
n
et
al
.2
1
c
Bo
ld
te
xt
in
di
ca
te
s
va
lu
es
th
at
ar
e
st
at
is
tic
al
ly
si
gn
iﬁ
ca
nt
.
RESULTS
44
NIHR Journals Library www.journalslibrary.nihr.ac.uk
grommets alone) group (unadjusted RD −6.9%, 95% CI −17.5% to 4.9%; unadjusted RR 0.79,
95% CI 0.52 to 1.20; adjusted RR 0.98, 95% CI 0.69 to 1.38)
¢ ≥ 4 years: the proportion who failed at 12 months was 50.6% in the adenoidectomy group
(adenoidectomy with or without grommets) and 69.6% in the no adenoidectomy (non-surgical or
grommets alone) group (unadjusted RD −19.0%, 95% CI −26.1% to −12.0%; unadjusted RR
0.73, 95% CI 0.64 to 0.82; adjusted RR 0.77, 95% CI 0.68 to 0.86).
Secondary outcomes
The signiﬁcant interaction effects for the secondary outcomes are reported in Table 12 and
Appendix 15. This extends the analysis beyond that originally proposed but avoids the risk of missing
a signiﬁcant ﬁnding.
Four or more acute otitis media episodes per year
l Indication: recurrent AOM – a signiﬁcant interaction effect (p = 0.05) was found for age: < 2 years
compared with ≥ 2 years:
¢ < 2 years: the proportion of children with four or more AOM episodes per year was 12.7% in the
adenoidectomy group (adenoidectomy with or without grommets) and 18.7% in the no
adenoidectomy (non-surgical or grommets alone) group (unadjusted RD −6.0%, 95% CI −11.6%
to −0.4%; unadjusted RR 0.68, 95% CI 0.46 to 0.99; adjusted RR 0.71, 95% CI 0.49 to 1.02)
¢ ≥ 2 years: the proportion of children with four or more AOM episodes per year was 21.2% in the
adenoidectomy group (adenoidectomy with or without grommets) and 3.1% in the no
adenoidectomy (non-surgical or grommets alone) group (unadjusted RD 18.1%, 95% CI 2.9% to
33.3%; unadjusted RR 6.79, 95% CI 0.88 to 52.10; adjusted RR 4.80, 95% CI 0.64 to 35.7).
Number of acute otitis media episodes in the first 12 months of follow-up
l Indication: recurrent AOM – a signiﬁcant interaction effect (p = 0.01) was found for age: < 2 years
compared with ≥ 2 years:
¢ < 2 years: the number of AOM episodes in the ﬁrst 12 months was 1.5 episodes [standard
deviation (SD) 1.7 episodes] in the adenoidectomy group (adenoidectomy with or without
grommets) and 2.0 episodes (SD 2.1 episodes) in the no adenoidectomy (non-surgical or grommets
alone) group (adjusted mean difference −0.5 episodes, 95% CI −0.8 to −0.2 episodes)
¢ ≥ 2 years: the number of AOM episodes in the ﬁrst 12 months was 1.6 episodes (SD 2.0 episodes)
in the adenoidectomy group (adenoidectomy with or without grommets) and 0.8 episodes
(SD 1.1 episodes) in the no adenoidectomy (non-surgical or grommets alone) group (adjusted mean
difference 0.6 episodes, 95% CI −0.1 to 1.4 episodes).
l Indication: persistent OME – a signiﬁcant interaction effect (p = 0.05) was found for age: < 4 years
compared with ≥ 4 years:
¢ < 4 years: the number of AOM episodes in the ﬁrst 12 months was 0.6 episodes (SD 0.1 episodes)
in the adenoidectomy group (adenoidectomy with or without grommets) and 0.8 episodes
(SD 0.1 episodes) in the no adenoidectomy (non-surgical or grommets alone) group (adjusted mean
difference −0.1 episodes, 95% CI −0.1 to 0.4 episodes)
¢ ≥ 4 years: the number of AOM episodes in the ﬁrst 12 months was 1.0 (SD 0.2 episodes) in the
adenoidectomy group (adenoidectomy with or without grommets) and 1.5 episodes (SD 0.2 episodes)
in the no adenoidectomy (non-surgical or grommets alone) group (adjusted mean difference
−0.4 episodes, 95% CI −0.8 to 0.0 episodes).
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Surgery during the first 12 months of follow-up
l Indication: persistent OME – a signiﬁcant interaction effect (p < 0.01) was found for age: < 4 years
compared with ≥ 4 years:
¢ < 4 years: the proportion having additional surgery was 10.7% in the adenoidectomy group
(adenoidectomy with or without grommets) and 9.9% in the no adenoidectomy (non-surgical or
grommets alone) group (unadjusted RD 0.3%, 95% CI −7.3% to 8.0%; unadjusted RR 1.03,
95% CI 0.48 to 2.21; adjusted RR 1.03, 95% CI 0.46 to 2.30)
¢ ≥ 4 years: the proportion having additional surgery was 2.2% in the adenoidectomy group
(adenoidectomy with or without grommets) and 18.8% in the no adenoidectomy (non-surgical or
grommets alone) group (unadjusted RD −16.6%, 95% CI −20.7% to −12.5%; unadjusted RR
0.12, 95% CI 0.05 to 0.25; adjusted RR 0.13, 95% CI 0.06 to 0.27).
Time with effusion during the first 12 months of follow-up
l Indication: persistent OME – a signiﬁcant interaction effect (p = 0.05) was found for age: < 4 years
compared with ≥ 4 years:
¢ < 4 years: the number of weeks with effusion in the ﬁrst 12 months was 11.1 weeks
(SD 1.7 weeks) in the adenoidectomy group (adenoidectomy with or without grommets) and
18.2 weeks (SD 2.4 weeks) in the no adenoidectomy (non-surgical or grommets alone) group
(adjusted mean difference −3.2 weeks, 95% CI −6.4 to −0.1 weeks)
¢ ≥ 4 years: the number of weeks with effusion in the ﬁrst 12 months was 23.2 weeks
(SD 0.9 weeks) in the adenoidectomy group (adenoidectomy with or without grommets) and
30.1 weeks (SD 0.9 weeks) in the no adenoidectomy (non-surgical or grommets alone) group
(adjusted mean difference −6.6 weeks, 95% CI −9.0 to −4.3 weeks).
Subgroup analysis: secondary comparisons
For most secondary outcomes the numbers per subgroup were < 15. The results are therefore inherently
unstable and these analyses are not included.
Adenoidectomy with unilateral or bilateral grommets compared with
non-surgical treatment
Primary outcome
No signiﬁcant interactions were found for either indication.
Secondary outcomes
No signiﬁcant interactions were found for either indication.
Adenoidectomy with unilateral or bilateral grommets compared
with unilateral or bilateral grommets
Primary outcome
As above we found a difference in subgroup effects based on the indication for surgery (a history of
recurrent AOM compared with a history of persistent OME). However, in this instance we found a
difference only when the indication was recurrent AOM (Table 13).
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l Indication: recurrent AOM – a marginal signiﬁcant interaction effect (p = 0.06) was found for age:
< 2 years compared with ≥ 2 years:
¢ < 2 years: the proportion who failed at 12 months was 10.9% in the adenoidectomy with
grommets group and 16.5% in the grommets only group (unadjusted RD −5.7%, 95% CI −12.1%
to 0.8%; unadjusted RR 0.66, 95% CI 0.41 to 1.06; adjusted RR 0.69, 95% CI 0.43 to 1.11)
¢ ≥ 2 years: the proportion who failed at 12 months was 18.2% in the adenoidectomy with
grommets group and 2.6% in the grommets only group (unadjusted RD 15.6%, 95% CI 3.2% to
28.1%; unadjusted RR 7.09, 95% CI 0.93 to 54.2; adjusted RR 4.96, 95% CI 0.69 to 35.52).
Secondary outcomes
The signiﬁcant interaction effects for the secondary outcomes are reported in Table 13 and
Appendix 16. This extends the analysis beyond that originally proposed but avoids the risk of missing a
signiﬁcant ﬁnding.
Number of acute otitis media episodes in the first 12 months of follow-up
l Indication: recurrent AOM – a signiﬁcant interaction effect (p = 0.03) was found for age: < 2 years
compared with ≥ 2 years:
¢ < 2 years: the number of AOM episodes in the ﬁrst 12 months was 1.3 episodes (SD 1.5 episodes)
in the adenoidectomy with grommets group and 1.5 episodes (SD 1.7 episodes) in the grommets
only group (adjusted mean difference −0.2 episodes, 95% CI −0.5 to 0.7 episodes)
¢ ≥ 2 years: the number of AOM episodes in the ﬁrst 12 months was 1.6 episodes (SD 2.0 episodes)
in the adenoidectomy with grommets group and 0.8 episodes (SD 1.1 episodes) in the grommets
only group (adjusted mean difference 0.8 episodes, 95% CI −0.0 to 1.6 episodes).
Surgery during the first 12 months of follow-up
l Indication: persistent OME – a marginally signiﬁcant interaction effect (p = 0.06) was found for age:
< 4 years compared with ≥ 4 years:
¢ < 4 years: the proportion having additional surgery was 7.6% in the adenoidectomy with
grommets group and 8.0% in the grommets only group (unadjusted RD −0.4%, 95% CI −0.8%
to 0.7%; unadjusted RR 0.95, 95% CI 0.36 to 2.52; adjusted RR 0.81, 95% CI 0.31 to 2.15)
¢ ≥ 4 years: the proportion having additional surgery was 2.2% in the adenoidectomy with
grommets group and 12.5% in the grommets only group (unadjusted RD −10.3%, 95% CI
−14.4% to −6.3%; unadjusted RR 0.18, 95% CI 0.08 to 0.39; adjusted RR 0.20,
95% CI 0.09 to 0.44).
Adenoidectomy without grommets compared with non-surgical treatment
Primary outcome
No signiﬁcant interactions were found for either indication.
Secondary outcomes
No signiﬁcant interactions were found for either indication.
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Adenoidectomy without grommets compared with unilateral
or bilateral grommets
Primary outcome
No signiﬁcant interactions were found for either indication.
Secondary outcomes
No signiﬁcant interactions were found for either indication.
Sensitivity analysis
A series of sensitivity analyses using alternative deﬁnitions of failure at 12 months showed similar results.
A per-protocol analysis, in which we excluded children in the no adenoidectomy group who nevertheless
underwent adenoidectomy, showed similar results to the intention-to-treat analysis. In the as-treated
analysis, in which children from the no adenoidectomy group who had their adenoid removed were
analysed in the adenoidectomy group, the effect of adenoidectomy was no longer signiﬁcant but the
direction of the effects was similar when using a deﬁnition of failure that excluded additional surgery. The
results of the per-protocol and as-treated analyses for the main comparison are shown in Appendix 15.
Adverse effects or events
As adverse effects and events are important secondary outcomes we report the available data here. We
sought evidence of the speciﬁc complications of adenoidectomy: primary and secondary haemorrhage,
hypernasal speech and the complications of general anaesthesia. Two studies11,20 reported data on
postoperative complications and adverse effects, three12,16,17 reported that no surgery-related complications
had occurred and ﬁve15,18,19,21,52 did not report on complications or adverse effects.
The adenoidectomy complication reported by Casselbrant et al.11 was a single child in the adenoidectomy
with grommets group (1/32, 3.1%) in whom difﬁculty during anaesthesia led to the child subsequently
being treated with grommets only. In the MRC study20 one child (1/165, 0.6%) had to return to theatre
because of postoperative haemorrhage.
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Chapter 4 Discussion
Main ﬁndings
This IPD meta-analysis includes 10 trials involving 1761 children with OM (recurrent AOM or persistent
OME). Nine out of the 10 studies made a comparison between adenoidectomy and grommets and
grommets alone, that is, the direct comparisons from these nine studies provide the most robust evidence.
Most of the included studies had a low risk of bias. Twelve months after surgery, children who have had
their adenoid removed have a greater chance of clinical improvement. The size of that effect is, in general,
small but persists for at least 2 years after surgery. The RD of 13% corresponds to a NNT of eight to
prevent one failure; the adjusted RR was 0.76 (95% CI 0.69 to 0.85). Improvement was seen in outcomes
that were not found to be signiﬁcant in a previous non-IPD meta-analysis,28 for example lower number
of AOM episodes, less time with effusion, less additional surgery, less hearing loss and improvement in
hearing levels up to 2 years after surgery. Effect sizes are small but consistent, with NNTs ranging from
5 to 21.
To predict which children are likely to have a prolonged duration of their OM we looked speciﬁcally at
those children who did not receive any surgery at all (adenoidectomy or grommets) at study entry and
who are likely to best reﬂect the natural history of untreated disease (‘non-surgical children’). Of these
children 56% failed to improve at 12 months. The only factor that predicted which children had a
prolonged duration of their OM was the indication for surgery (recurrent AOM or persistent OME). In
children with recurrent AOM as the indication for intervention 38% failed to improve, whereas in children
with persistent OME as the indication for intervention 89% failed to improve.
In the subgroup analyses we found the anticipated differences in effects based on the indication for
surgery (recurrent AOM compared with persistent OME). Two subgroups of children are most likely to
beneﬁt from adenoidectomy. These are (1) children with recurrent AOM aged < 2 years and (2) older
children aged ≥ 4 years with persistent OME.
The proportion of children with recurrent AOM aged < 2 years who failed at 12 months was 16% in
the adenoidectomy group and 27% in the group who did not have adenoidectomy. This RD of 12%
corresponds to a NNT of nine to prevent one failure. The adjusted RR was 0.63 (95% CI 0.47 to 0.85).
In contrast, in children aged ≥ 2 years, no beneﬁt of adenoidectomy was seen.
The proportion of children with persistent OME aged ≥ 4 years who failed at 12 months was 51% in
the adenoidectomy group and 70% in the group who did not have adenoidectomy. This RD of 19%
corresponds to a NNT of six to prevent one failure. The adjusted RR was 0.77 (95% CI 0.68 to 0.86).
In children aged < 4 years no signiﬁcant beneﬁt of adenoidectomy was seen.
These ﬁndings relate to the main comparison, that is, adenoidectomy or adjuvant adenoidectomy
(adenoidectomy with grommets) compared with no surgery or grommets alone. When the subgroup
analyses were repeated with our secondary comparisons, the statistical power to detect signiﬁcant
interactions was necessarily reduced. However, we still found a difference in subgroup effects based on
indication for surgery and age when adenoidectomy with grommets was compared with grommets alone
(the ‘adding adenoidectomy’ comparison, assessing the effect of so-called ‘adjuvant adenoidectomy’).
Age was found to be of inﬂuence only in the recurrent AOM group.
In the development of the predictive model age was not identiﬁed as a factor predicting those children
with a prolonged (12-month) duration of their OM. We had anticipated that it might be a factor and that
there might be a detectable interaction between age and indication. Yet in the subgroup analysis, in
DOI: 10.3310/hta18050 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 5
51
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Boonacker et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
children with recurrent AOM, age was a factor associated with failure at 12 months in young children
aged < 2 years compared with older children. The reason for this is that almost all of the children in the
trials that evaluate interventions for recurrent AOM are young – aged < 2 years. As one moves from
analysing the whole group to subgroups, the recurrent AOM subgroup and the younger children
(< 2 years) subgroup contain the same children. Identifying an interaction between indication and age was
therefore impossible: there were insufﬁcient data to detect an interaction even if one exists because
there are not enough older children (aged ≥ 4 years) in the recurrent AOM group and also not enough
younger children (aged < 2 years) in the persistent OME group.
These ﬁndings support the general understanding of at least two clinical entities within a spectrum of OM
across the age range from birth to 12 years: recurrent AOM in younger children (aged < 2 years) and
persistent OME in older children (aged ≥ 4 years). Children aged ≥ 4 years with recurrent AOM are rare
within our IPD data set either because the trial entry criteria speciﬁcally excluded them (we know that this
is true for some of our included trials – all of the trials that enrolled children with recurrent AOM only
speciﬁcally excluded children aged > 2 years) or because this combination is a rare occurrence. We did in
fact include trials in which children aged > 2 years with recurrent AOM could have been included, but they
are present in very low numbers.
Strengths and limitations
The main strength of our study is that by reanalysing the original data from 10 trials of adenoidectomy we
could include 1761 children in our IPD meta-analysis, which gave us the power to identify subgroups that
could beneﬁt most from adenoidectomy.
Some of our ﬁndings deserve further discussion:
1. We contacted the principal investigators of all 15 eligible RCTs to ask if they were willing and able to
provide their raw data. We were unable to contact the principal investigator of one trial24 and the
data for four older trials (1978–99)14,22,23,25 were no longer available. The main characteristics of these
ﬁve trials are, however, much the same as those of the 10 included trials. Moreover, the overall results
of our subset of 10 trials are very similar to the overall results reported by the Cochrane review28 that
did include all of these trials. A funnel plot of the included studies (not shown) also indicates that
publication bias is unlikely in this IPD meta-analysis.
2. Not all variables were measured in all eligible trials so we chose to use a composite outcome, failure
at 12 months, deﬁned as failing on at least one out of four components. Only one of the 10 included
trials measured all four components; six trials measured three of the four components and the other
three trials measured two of the four components (see also Appendix 10). Furthermore, we could not
study all potential effect modiﬁers. The total number of baseline variables measured in the included
trials varied between 9 and 39 per trial. Of the variables of interest, only three were measured in all
10 trials.
3. In our prognostic analyses we included only those children allocated to non-surgical treatment. This is
appropriate because adenoidectomy with or without grommets might inﬂuence the course of the
disease and might result in an invalid natural history model.
4. We did not study all potential subgroups. We selected previously established predictors of a prolonged
course and some clinically relevant variables and performed stratiﬁed analyses only for those variables
that showed a signiﬁcant p-value (< 0.1) for interaction in the regression model. Did we therefore
‘miss’ a relevant subgroup? Our approach follows the recommendations for the study of subgroups.
The strength of this approach is that our prognostic analyses revealed only a few relevant subgroups.
By limiting the number of subgroup analyses we minimise the likelihood of false-positive ﬁndings
(type I error) that could be caused by multiple testing. We were unable to study some clinically
relevant subgroups that might beneﬁt more from adenoidectomy, such as children with Down
syndrome, because such children were excluded from the individual trials. The experience of many
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clinicians – that these and other subgroups of children beneﬁt more from adenoidectomy than
others – has not yet been evidenced in RCTs. Neither could we study the effect of adenoidectomy in
children with differing baseline hearing levels as hearing was not assessed in all included studies.
In the studies that did assess hearing at baseline, the effects of adenoidectomy did not differ between
groups with different baseline hearing levels.
5. Although an overall measure of severity including both persistent AOM and recurrent OME is not
available, frequency of AOM, duration of symptoms and degree of hearing loss are potential measures
of severity. They were included in the prognostic analyses and were not found to be of inﬂuence
when tested in the multivariate analyses.
6. Because of relatively wide variation in the speciﬁc surgical interventions across the 10 included trials,
we had to make a fairly large number of comparisons, which renders interpretation of the results
more difﬁcult and introduces a degree of obfuscation. Although we focused on our main comparison,
adenoidectomy with or without grommets compared with non-surgical treatment or grommets only,
we also compared adenoidectomy with unilateral or bilateral grommets with non-surgical treatment;
adenoidectomy with unilateral or bilateral grommets with unilateral or bilateral grommets;
adenoidectomy without grommets with non-surgical treatment; and adenoidectomy without
grommets with unilateral or bilateral grommets. Because of the smaller numbers in some of these
secondary comparisons, the subgroup effects are inevitably less obvious. However, there were no
inconsistencies in effect directions.
7. In all of our studies short-term tubes were used; therefore, ‘tube life’ is unlikely to have inﬂuenced
the results.
8. In our pooled analysis of failure at 12 months we combined several outcomes, which were measured
slightly differently across the 10 included trials. Sensitivity analysis using an alternative set of
deﬁnitions of ‘failure’ showed similar results. Furthermore, the time points for follow-up assessments
varied across the included trials (e.g. some took measurements every month, others every 3 or
6 months). As a result, a measurement artefact cannot be precluded. To evaluate this further we
undertook a sensitivity analysis with the trials that assessed the participants most frequently and found
that the results were consistent with the overall results.
9. We included trials that studied the effects of surgery in children with persistent OME as well as those
studying the effects of surgery in children with recurrent AOM or combinations of persistent OME and
recurrent AOM. We believe that these two clinical conditions, although distinctly deﬁned, are in fact
closely related as part of a spectrum of disease. Our analyses showed different effects based on the
indication for surgery for both the main effect and the subgroup effects. This conﬁrms that these two
indications should be distinguished in both clinical and research settings, with implications for clinical
practice and future research.
10. We chose a composite outcome as the included trials each used slightly different outcomes. It is
known that combined outcomes can make a treatment seem more or less effective than it really is,54
that is, higher event rates and larger treatment effects associated with less important components may
result in misleading impressions of the impact of treatment. We therefore performed sensitivity
analyses using different composite outcomes, which all showed similar results. By using such a
composite end point we were able to aggregate our data and generalise results. This was critical to
accomplish our aim of establishing which children beneﬁt more or less from adenoidectomy.
11. Some studies randomised ears rather than children, and it is self-evident that this applies only to the
insertion of grommets (i.e. in some studies a grommet was inserted unilaterally). The focus of our IPD
meta-analysis was the effect of adenoidectomy, and this intervention was always randomised to
children. We compared children and those randomised to adenoidectomy with/without grommets
with those randomised to non-surgical treatment or grommets only. Other comparisons included
adenoidectomy with unilateral or bilateral grommets compared with adenoidectomy without
grommets, and unilateral or bilateral grommets compared with non-surgical treatment.
We pooled the studies that randomised ears with those that randomised children. Sensitivity analysis
in which we excluded the (older) trials that randomised ears rather than children did not change
our results.
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12. We were unable to calculate adjusted RDs because of the calculation artefact that occurs when there
are zero events in a study.21 We decided to also present the unadjusted RDs as these are the easiest to
understand and interpret. In most cases the adjusted RR and the raw RR did not differ much,
suggesting that confounding is not a big issue.
13. Although informative, we did not compare (1) adenoidectomy plus unilateral or bilateral grommets
with adenoidectomy without grommets or (2) unilateral or bilateral grommets with non-surgical
treatment as these analyses do not fulﬁl the criteria for inclusion in this IPD meta-analysis.
14. Most data on recurrent AOM come from Finland and this may have inﬂuenced our results. Personal
communication with the authors of these Finnish trials led us to realise that early surgery for recurrent
AOM might be a cultural issue. Reasons for performing these trials included the high adenoidectomy
rate in Finland compared with that in other Scandinavian countries, for example Norway. The authors
also conﬁrmed that the number of children undergoing adenoidectomy has decreased since the
results of these trials were published. We are not aware of any societal or biological factors varying
across Western countries that may cause the effects of treatment in Finland to differ from the effects
of treatment in other countries.
15. In surgical trials such as those included in our IPD meta-analysis, only the children who are assigned to
the control arm, who do not undergo the operation under study, can transfer, that is, move to a
treatment arm because of persisting problems. Per-protocol analyses that exclude children who
transfer to the other arm of the trial will therefore underestimate the effect of treatment. Conversely,
analysing children on the basis of time spent in a treatment arm might overestimate or underestimate
this effect.
16. Finally, nine out of the 10 included studies made a comparison between adenoidectomy with
grommets and grommets alone. The comparisons from these nine studies therefore seem to provide
the most robust evidence.
Clinical implications
The effect of adenoidectomy seems to vary with age both in children with recurrent AOM and in children
with persistent OME. However, it may not be age per se that is relevant but rather the presence of
differing pathophysiological mechanisms in different age groups that serves as the modiﬁer, with age
simply being a proxy for these. OM is known to result from an interplay between microbial load and the
immune response. The Eustachian tube is the port of entry for middle ear pathogens from the
nasopharynx, but it also plays an important part in clearing middle ear secretions. One responsible
mechanism may relate to the relative immaturity of the immune response in younger children, particularly
those children aged < 2 years. As the immune response improves with age, problems with infection may
recede and those associated with a middle ear effusion, that is, hearing loss, become relatively more
apparent. This coincides with a period of social and behavioural change in the child’s life. Starting school
and becoming part of a peer group may be the factors that initiate concerns about performance and
increase awareness of the child’s hearing. More insight into the pathophysiology of OM is needed to
understand better the causal mechanisms of the subgroup effects. In the meantime, clinicians can still use
the information about age and indication as part of the shared decision-making process when deciding
with parents whether or not to operate on their child.
Like all health-care decisions, the decision whether or not to undertake adenoidectomy will be inﬂuenced
by existing local practice. It is extremely unusual for adenoidectomy to be undertaken in the UK in children
aged < 2 years for any indication other than obstructive sleep apnoea, when it may be performed with
tonsillectomy. In other northern European countries adenoidectomy is common in young children, as the
presence of such children in some of the included studies indicates.
In our analyses we found no evidence to support the suggestion by NICE that possible beneﬁts of
adenoidectomy should be considered in children selected for grommets for OME who also suffer from
respiratory symptoms. The number of upper respiratory tract infections was not a predictor of failure at
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12 months. However, this might be because upper respiratory tract infections were measured in only one
trial, resulting in a relatively low number of children in whom upper respiratory tract infections could be
studied as a predictor.
As with all interventions (and particularly in the case of surgical procedures), consideration must be given
to the ratio between beneﬁts and harms. In the children aged < 4 years a modest beneﬁt may easily be
outweighed by the potential risks and harms. Those same risks and harms are the reason why the
overall small beneﬁcial effect found for children of all ages should not be used as the rationale for treating
all children.
The trials included in this IPD meta-analysis provide very limited information on the adverse effects of
adenoidectomy, an understanding of which is clearly critical when undertaking a risk–beneﬁt analysis
before making a treatment decision.
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Chapter 5 Conclusions
Children with OM who have their adenoid removed have a greater chance of clinical improvement;eight children need to receive adenoidectomy to prevent one failure. Adenoidectomy is most beneﬁcial
in children aged ≥ 4 years with persistent OME (six children needing adenoidectomy to prevent one
failure). A smaller beneﬁcial effect was found in children with recurrent AOM aged < 2 years (nine children
needing adenoidectomy to prevent one failure). No beneﬁcial effect was seen in children aged < 4 years
with persistent OME or ≥ 2 with recurrent AOM.
The need to use a composite end point and the limited number of subgroup variables that could be
studied are factors that reduce the robustness of these results; however, we do not believe that these
factors reduce the validity of the conclusions.
As with all interventions (and in particular surgical procedures), consideration must be given to the balance
between beneﬁts and harms. Clinicians can discuss these issues with the parents of children with OM to
allow them to make an informed treatment decision.
Future research is required in a number of key areas, including deﬁning the best methods of selecting,
developing and administering patient-reported outcome measures (PROMs) to assess the value of
treatments for children with persistent OME and recurrent AOM and upper respiratory infections;
investigating the clinical effectiveness and cost-effectiveness of hearing aids and the use of interventions
to improve classroom acoustics for children with different degrees of persistence and severity of hearing
loss associated with OME; and investigating why professionals’ and parents’/carers’ treatment preferences
vary so much both nationally and internationally.
We do not understand why adenoidectomy works in different subgroups at different ages, nor its effects
in special populations, such as children with Down syndrome. We also need further research on the impact
and optimal management of otitis media in these special situations and others, such as in children with a
cleft palate or developmental problems.
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Appendix 1 Protocol
Which children with otitis media with effusion beneﬁt
most from adenoidectomy with or without grommets
(ventilation tubes)? An individual patient data meta-analysis
Authors: Maroeska Rovers, Martin Burton, Arno Hoes, Anne Schilder
Summary
Current evidence suggests that overall effects of adenoidectomy are limited. Nevertheless, in day-to-day
practice, both general practitioners and ENT-surgeons believe that certain subgroups of patients may
beneﬁt from adenoidectomy. So far, identifying these subgroups has been problematic, as the individual
trials have been too small to allow valid and reliable subgroup analyses to be performed. Consequently it is
likely that both over- and under-treatment occurs. The proposed Individual Patient Data (IPD) meta-analysis
will include the individual data of about 2000 children aged 10 months to 12 years who participated in 9
to 12 randomised controlled trials into the effectiveness of adenoidectomy.
We aim to:
1. predict which children referred for adenoidectomy have a higher risk for a prolonged course of their
upper respiratory tract infections, and
2. identify subgroups of children that most likely beneﬁt from adenoidectomy.
The current proposal will lead to a better diagnostic and treatment protocol for children with otitis media
for whom the general practitioner considers referral for adenoidectomy.
Background
Adenoidectomy is one of the most frequently performed surgical procedures in children in high-income
countries. Annual adenoidectomy rates differ, however, between countries. When considering rates per
10,000 children per year, they vary, being 127 in Belgium, 101 in the Netherlands, 39 in England and 24
and 17 in the United States and Canada, respectively.1
Indications for adenoidectomy include recurrent episodes of acute otitis media (AOM) and persistent otitis
media with effusion (OME).2 The operation involves removing the adenoid – a nasopharyngeal reservoir of
potential respiratory pathogens and a potential cause of obstruction of the nasal airway. Removal is
thought to improve Eustachian tube function.
We recently performed a Cochrane review, which showed a signiﬁcant beneﬁt of adenoidectomy as far as
the resolution of middle ear effusion in children with OME is concerned.3 However, the beneﬁt to hearing
is small and the effects on changes in the tympanic membrane are unknown. The risks of operating should
therefore be weighed against these potential beneﬁts. Furthermore, no beneﬁt of adenoidectomy was
found on AOM. However, in day-to-day general practice about one in ten children with otitis media is
referred to an ENT-surgeon and in some countries the vast majority of these children are selected for
surgery. This conﬁrms that both general practitioners and ENT-surgeons believe that certain subgroups of
patients may beneﬁt from adenoidectomy. The identiﬁcation of these subgroups has, however, been
problematic, as the individual trials performed so far were too small to perform valid and reliable subgroup
analyses. Consequently it is likely that both over- and under-treatment occurs. An IPD meta-analysis,
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i.e. a meta-analysis on the individual original data of previously performed trials, offers the unique
opportunity to identify subgroups more likely to beneﬁt from an intervention.4,5 Since IPD meta-analyses
include more detailed data, they have much more statistical power to carry out informative subgroup
analyses. Furthermore, by using individual patient data the ﬂexibility of subgroup analyses is enhanced.
Consequently, the estimated subgroup effects may be less inﬂuenced by misclassiﬁcation and (ecological)
bias. IPD meta-analysis therefore allows a more thorough assessment as to whether differences in
treatment effects across subgroups are spurious or not.6 An earlier IPD meta-analysis from our research
group in children with acute otitis media showed that such an approach is capable of identifying
subgroups of children that are most likely to beneﬁt from antibiotic therapy.7,8
Objective
In this IPD meta-analysis with the individual data of at least nine (but probably 12) randomized controlled
trials into the effectiveness of adenoidectomy including more than 2000 children aged 10 months to
12 years, we aim to:
1. predict which children referred for adenoidectomy have a higher risk for a prolonged course of their
upper respiratory tract infection
2. identify subgroups of children that beneﬁt most or are most likely to beneﬁt from adenoidectomy.
Methods
Design
We will perform an individual patient data meta-analysis with individual data of trials performed so far on
the effectiveness of adenoidectomy in children. Our previous IPD meta-analysis on the effect of
tympanostomy tubes in children9 will give us access to the data of four trials of the effects of the
combination of adenoidectomy and tympanostomy tubes, versus those of insertion of tympanostomy
tubes alone or watchful waiting.10–13 To study the effect of adenoidectomy in all clinically relevant
subgroups, we have also contacted the primary investigators (PIs) of all other existing adenoidectomy
trials,14–26 and asked them to provide the raw data of their trials. Of the 17 trials performed up to
now, 4 were performed before 1990 and the PIs have indicated that their data are no longer available.
Of the remaining 13 trials, the PIs of 9 have already agreed to participate in our IPD meta-analysis,
which underpins the international support of the current proposal. Three other PIs have shown interest,
but are awaiting approval by their IRB. The PI of the 13th trials has declined to collaborate in our
IPD meta-analysis.
Study population
In total data of at least 2000 children aged 10 months to 12 years selected for adenoidectomy are
available. Such a new dataset will offer the unique opportunity to identify which children beneﬁt most
from adenoidectomy. In 5 of the 12 eligible studies adenoidectomy (with or without myringotomy) is
compared with non-surgical treatment; in 3 trials adenoidectomy with tympanostomy tubes is compared
with adenoidectomy alone; and in 4 trials adenoidectomy with bilateral insertion of tympanostomy tubes is
compared with bilateral tympanostomy tubes alone. Follow-up varies from 6 to 36 months.
Subgroups
Clinically relevant subgroups that will be studied include: age (≤ 2 years vs. > 2 years), sex, season
(winter vs. summer), attending day-care, passive smoking, being breast fed, vaccine status, atopy, number
of previous episodes of upper respiratory tract infections (including otitis media), duration of symptoms,
middle ear impedance and baseline hearing level. Age, sex, season, previous episodes of otitis and
impedance are measured in all nine trials, whose principal investigators have already agreed to participate.
Information on attending a day-care centre, passive smoking, atopy, being breastfed, and baseline
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hearing level are available in 5 trials. Vaccination status is measured in 3 trials, whereas 4 other trials were
performed before the pneumococcal vaccine was available.
The subgrouping variables have been assessed in similar ways and can therefore be pooled over the trials.
As the pathogenesis of otitis media is known to be multifactorial, children with more than one
predisposing factor may have more persistent or severe disease and hence might beneﬁt more from
treatment with adenoidectomy than children with only one such factor. To study this possibility, we will
also study the combinations of predictors. Furthermore, separate analyses will be performed for the groups
that also received tympanostomy tubes and those that did not.
Outcomes
The primary outcome is number of otitis episodes in the ﬁrst 12 months after adenoidectomy. The
deﬁnitions of acute otitis media (AOM) and otitis media with effusion (OME) proposed by the American
Association of Family Physicians (AAFP) and the American Academy of Pediatrics (AAP) will be used.
For AOM this is: acute onset of signs and symptoms, the presence of middle ear effusion (bulging of the
tympanic membrane, or limited or absent mobility of the tympanic membrane, or air–ﬂuid level behind the
tympanic membrane, or otorrhoea), and signs and symptoms of middle ear inﬂammation (distinct
erythema of the tympanic membrane or distinct otalgia).
For OME this is: presence of ﬂuid in the middle ear, without signs and symptoms of acute ear infection as
diagnosed by (pneumatic) otoscopy or tympanometry. Effusion should be measured with tympanometry,
mean hearing loss with audiometry.
The number of episodes in the ﬁrst 12 months was chosen as our primary outcomes since it has been
measured in all available trials. We also believe this is an important outcome both from a patient and a
societal point of view. The high rate of spontaneous recovery in the short term also mandates a follow-up
period of this length.
Secondary outcomes that will be studied are:
1. treatment failures after 3, 6, and 12 months
2. acute otitis media
(a) number of otitis episodes per year
(b) number of days per episode and per year
(c) proportion of children with recurrent episodes.
3. otitis media with effusion
(a) number of episodes per year
(b) number of days per episode and per year
(c) proportion of children with recurrent episodes
(d) prevalence at 3, 6, 12 and 24 months.
4. mean hearing loss at 6, 12, and 24 months
5. adverse effects.
Treatment failure will be deﬁned as a composite outcome consisting of 4 independent components:
1. no improvement in number of OM episodes per person month
2. no improvement in prevalence of OME at follow-up visits
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3. no improvement in mean hearing level at follow-up visits
4. crossing over from watchful waiting to surgical treatment arm.
We did not choose this outcome as our primary outcome since not all components are measured in
all trials.
The hearing loss is deﬁned as the main air conduction which should be measured with audiometry.
Adverse events include:
1. changes to the ears (including tympanic membrane: atrophy, tympanosclerosis, retraction of the pars
tensa and pars ﬂaccida and cholesteatoma) and
2. postoperative bleeding and velo-pharyngeal insufﬁciency.
Statistical analysis
To minimise bias and to increase statistical efﬁciency, we will impute the missing data per trial using the
linear regression method (MVA analyses) available in SPSS (SPSS for Windows, version 15.0, SPSS Inc.).
Such imputation is based on the correlation between each variable with missing values and all other
variables as estimated from the set of complete subjects. We will impute missing values only within trials.
To assess the ﬁrst research question, i.e. to predict which children referred for adenoidectomy have a higher
risk for a prolonged course of their upper respiratory symptoms, the association between each subgrouping
variable and each of the outcomes will be examined by univariate logistic regression analyses. Predictors
that are univariately associated with the outcome (p-value > 0.10) will be included in multivariate logistic
regression analyses. The model will be reduced by excluding predictors from the model with a p-value of
> 0.05. The predictive accuracy of the models will be estimated by their reliability/callibrations (goodness of
ﬁt) using Hosmer and Lemeshow tests. The model’s ability to discriminate between children that will or not
develop the outcome will be estimated by the area under the receiver-operating curve (ROC) of the model.
The ROC area is a suitable parameter to summarise the discriminative or predictive value and can range
from 0.5 (no discrimination, like a coin ﬂip) to 1.0 (perfect discrimination). In addition, we will calculate the
absolute risks of a prolonged course across combinations of independent predictors.
To answer the second research question, ﬁrst the effect of adenoidectomy will be quantiﬁed by calculating
relative risks (RR), rate differences (RD), mean differences, numbers needed to treat (NNT) and their 95%
conﬁdence intervals (CI). To assess whether the effect of adenoidectomy is modiﬁed by the identiﬁed
prognostic factors, a random effect logistic and linear regression analysis will be performed. In this
saturated model adenoidectomy (yes vs. no), the potential effect modiﬁer, a dummy for the particular
study, and an interaction term (adenoidectomy × potential effect modiﬁer) will be included as independent
variables, and the outcomes as dependent variables. Finally, sensitivity analyses, for example, including only
those trials that measured the outcomes at the same moment, will be performed to assess the robustness
of the ﬁndings. All analyses will be performed according to the intention-to-treat principle.
Time schedule
The research will start in 2011. A time line is provided below.
The proposal will be undertaken in Utrecht by a PhD student (Chantal Boonacker) under primary
supervision of Professor Maroeska Rovers (clinical-epidemiologist, Utrecht) and Dr. M. Burton
(ENT-surgeon, Oxford) and supported by a systematic reviewer based in Oxford. Professor Arno Hoes
(clinical-epidemiologist, Utrecht), Professor Anne Schilder (Paediatric ENT-surgeon and clinical trialist, Utrecht
and London) and Professor George Browning (ENT-surgeon with special expertise in otitis media trials) will
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be available for further support. Project management and administrative support will be provided by staff
from the Cochrane ENT Disorders Group in Oxford.
The PIs of the original trials will also be involved by means of regularly updates. The commitment and
enthusiasm of several has been demonstrated by their already having provided their raw data. A formal
meeting will be held in Oxford (September 2012) to discuss the results and funding for the senior PIs to
travel to this meeting (several from the USA) has been included in the budget. It seems likely that new
research questions will emerge from this work and an important element of this project is to continue a
process of international engagement and dialogue with the world’s most experienced otitis media triallists
to ensure that the results of this review are used to best effect.
If statistical questions or problems arise, which Maroeska Rovers cannot solve, she will consult her
colleagues from the Cochrane IPD meta-analysis methods group, i.e. Mike Clarke, Jayne Thierney or Lesley
Clarke. For more details see the table at the following page.
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Appendix 2 Adaptation of the study protocol
As anticipated for any IPD meta-analysis, most adaptations were made after data collection andfollowing discussion with the principal investigators and/or study representatives of those studies
included in the meta-analysis. Two face-to-face meetings were held (Amsterdam, the Netherlands,
21 May 2012, and Oxford, UK, 3 September 2012).
Methods
Design and study population
In the protocol, studies that compared adenoidectomy with grommets compared with adenoidectomy
without grommets were mentioned. However, these studies do not fulﬁl the inclusion criteria as we
sought studies in which one comparator was either non-surgical treatment or grommets only. The studies
of Vlastos35 (who had agreed to participate and provide data) and Popova32 (who declined to participate)
were therefore excluded.
In the protocol it was mentioned that the follow-up of the trials that had been undertaken varied from six
to 36 months. However, to be eligible for inclusion in this IPD meta-analysis, studies needed to have
followed up participants for at least 12 months since a six-month follow-up period was deemed to be too
short. This resulted in one study, mentioned in the protocol (Fiellau-Nikolajsen,13 not being eligible.
However, this study would not have been included even had studies with six months follow-up been
eligible, since we were unable to contact the principal investigator, making individual patient
data unavailable.
All of these factors affected the number of trials and children that we had thought we might be able to
include. On the other hand, one new trial was published and included, resulting in 15 eligible studies.
Subgroups
Based on the suggestions of the PIs, several clinically relevant subgroups were added to the list of
prognostic factors deﬁned a priori. The ﬁnal list includes (additions underlined):
1. age (≤ 2 years versus > 2 years and ≤ 4 years versus > 4 years)
2. sex
3. indication
4. season (winter vs. summer)
5. day-care attendance
6. passive smoking
7. breastfeeding
8. PCV vaccine status
9. atopy
10. allergy
11. number of previous episodes of upper respiratory tract infections (including otitis media)
12. number of previous episodes of otitis media
13. duration of symptoms
14. age at onset
15. middle ear impedance/OME present at study entry
16. baseline hearing level.
In practice, not all of the desired factors could be included in the univariate analyse. The reasons included
low numbers or different deﬁnitions across studies.
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The comparisons of the interventions were worked out in detail:
1. adenoidectomy with or without grommets compared with non-surgical treatment or grommets only
(main comparison)
2. adenoidectomy with uni- or bilateral grommets compared with non-surgical treatment
3. adenoidectomy with uni- or bilateral grommets compared with uni- or bilateral grommets
4. adenoidectomy without grommets compared with non-surgical treatment
5. adenoidectomy without grommets compared with uni- or bilateral grommets.
We did not compare the following interventions since these analyses do not fulﬁl the criteria for inclusion
in this IPD meta-analysis:
1. adenoidectomy with uni- or bilateral grommets compared with adenoidectomy without grommets
2. uni- or bilateral grommets compared with non-surgical treatment.
Outcomes
The most notable adaptation was the decision to change the primary outcome from ‘number of otitis
media episodes’ to ‘failure at 12 months’ – a composite endpoint which was already included in the
protocol as a secondary outcome. When our study was underway and we were analysing the available
datasets, we realised that data on the original desired primary outcome would not be available, because
the original trialists did not evaluate outcomes in the same way. As is usual in many IPD meta-analyses,
rather than presenting an ‘empty’ review of little utility we sought – through consensus with clinicians,
including the original trialists – to develop a composite primary outcome that allowed inclusion of all of
the trials. The aim of this is, of course, to make maximum use of the available information to develop a
robust answer to the clinical questions posed. We emphasise to those who may be unfamiliar with this
speciﬁc form of secondary research that re-deﬁning a primary outcome in this way is signiﬁcantly different
from changing outcomes in primary research.
The composite primary outcome used was ‘failure at 12 months’, deﬁned as one or more of the
following components:
1. four or more AOM episodes (including episodes of otorrhoea) per year
2. presence of effusion for ≥ 50% of time
3. need for additional surgery
4. hearinga improved by less than 10 dB.
aHearing was expressed as a mean air conduction hearing level measured by age-appropriate audiometry
(if possible averaged over 500, 1000, 2000 and 4000 Hz). In all children the binaural average was taken.
This includes trials that used unilateral grommets and randomised ears rather than children.
The choice of this primary outcome also had consequences for the secondary outcomes. Based on the
availability of data, the time points for the secondary outcomes were changed from 3, 6, 12 and
24 months to 6, 12, 18 and 24 months.
APPENDIX 2
74
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Secondary outcomes
1. Each of the individual items used as part of the deﬁnition of ‘failure at 12 months’. That is:
¢ four or more AOM episodes/year
¢ presence of effusion for ≥ 50% of time
¢ need for additional surgery
¢ hearing improved by less than 10 dB.
2. Number of episodes of AOM during follow-up:
¢ in the ﬁrst 6, 12, 18 and 24 months.
3. Time with effusion during follow-up measured in number of weeks:
¢ in the ﬁrst 6, 12, 18 and 24 months.
4. Additional surgery during follow-up:
¢ in the ﬁrst 6, 18 and 24 months.
5. Average hearing loss measured in dBHL:
¢ after 6, 12, 18 and 24 months follow-up.
6. Improvement in hearing level < 10 dB:
¢ after 6, 18 and 24 months follow-up.
7. Adverse effects and events (including morbidity of surgery).
Statistical analysis
For Research Question 2a: to evaluate the overall effect of adenoidectomy,
with or without grommets on otitis media using these individual patient data
We quantiﬁed the overall effect of the interventions for all comparisons listed above (see also Figure 1a
and b). We used Review Manager 5 to create forest plots presenting both RDs and RRs for the main
effects. We also calculated relative risks (RR), rate differences (RD), numbers needed to treat (NNT) and the
95% conﬁdence intervals (CI) for each of these using regression analyses.
We were unable to calculate adjusted RDs due to the calculation artefact which occurs when there are
zero events in a study (in this case that of Nguyen et al.21). Therefore, we calculated unadjusted RDs with a
binominal model using an identity link:
YðfailureÞ ¼ αþ β  intervention ð7Þ
To adjust for a potential study effect we also performed a Poisson regression analysis with robust standard
errors, which enabled us to calculate an adjusted RR:
LogðfailureÞ ¼ αþ β  intervention þ β  dummy study ð8Þ
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For continuous outcomes we calculated an adjusted mean difference:
YðfailureÞ ¼ αþ β  intervention þ β  dummy study ð9Þ
For Research Question 2b. To identify those subgroups of children who
beneﬁt most, or are most likely to beneﬁt, from adenoidectomy with or
without grommets.
To assess whether the effect of the intervention under study was modiﬁed by the identiﬁed prognostic
factors, we performed an analysis using a binominal model with an identity link, including an
interaction effect.
YðfailureÞ ¼ αþ β  intervention subgrouping variable ð10Þ
To adjust for study and the subgrouping variable(s) we also performed a Poisson regression analysis with
robust standard errors including both interaction terms and potential confounders (i.e. study and age)
to calculate adjusted RR and their 95% conﬁdence intervals.
We used the Wald statistic from the adjusted Poisson regression to study the signiﬁcance of the
interaction term.
LogðfailureÞ ¼ αþ β interventionþ β subgrouping variableðsÞ þ β dummy study
þ β intervention subgrouping variableðsÞ ð11Þ
For continuous outcomes we calculated an adjusted mean difference:
YðfailureÞ ¼ αþ β interventionþ β subgrouping variableðsÞ þ β dummy study
þ β intervention  subgrouping variableðsÞ ð12Þ
We will only present subgroup effects for those variables that showed a signiﬁcant interaction effect
(P ≤ 0.1) and for subgroups with sufﬁcient numbers (> 15) to present stratiﬁed results. We used our clinical
experience and reasoning and decided a priori to include age and indication as potential subgroup
variables. Furthermore we decided to examine subgroup effects in the two distinct populations deﬁned by
the indication for surgery – recurrent AOM versus persistent OME.
Since many of the subgroup comparisons are between studies rather than within study, we will not
present forest plots for the subgrouping variables, but tables with the RD, RR and adjusted RRs from the
regression analyses.
We decided not to impute missing data due to the low number of missing data points within the included
trials. Furthermore, we decided not to impute data across trials in situations where a variable was
completely missing from a trial. We found in an earlier study that imputation of missing data across trials
might lead to bias, as association of covariates might differ across the included studies.30
In addition to the intention-to-treat analysis, we also performed three sensitivity analyses to assess the
robustness of our ﬁndings. In the ﬁrst we performed a per protocol analysis in which we excluded the
children who did not follow the protocol to which they were randomised. The second was an as treated
analysis in which we analysed the children according to the treatment they received. In the third we used
an alternative set of deﬁnitions of failure at 12 months as the outcome. We performed all sensitivity
analyses only for the primary outcome of the main comparison.
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All analyses were performed with SPSS, version 20 (IBM Corp. Released 2011. IBM SPSS Statistics for
Windows, Version 20.0. Armonk, NY: IBM Corp.) and Rothman’s Episheet (11 June 2008).
Time schedule
The research did not start in April 2011 as suggested by the timeline, but in December 2011. The formal
meeting was indeed held in September 2012 in Oxford, United Kingdom and was preceded by an informal
meeting during the ESPO conference in Amsterdam, the Netherlands.
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Appendix 3 Search strategies
Date: 30 March 2009, updated on 7 June 2012.
Cochrane Central Register of Controlled Trials
#1 MeSH descriptor Adenoidectomy explode all trees
#2 MeSH descriptor Adenoids explode all trees with qualiﬁer: SU
#3 adenoidectom* or adenotonsillectom* or adenotonsilectom* or adeno NEXT tonsillectomy* or adeno NEXT
tonsilectom*
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Adenoids explode all trees
#6 adenoid* or adenotonsil*
#7 (#5 OR #6)
#8 MeSH descriptor Surgical Procedures, Operative explode all trees
#9 (surg*:ti or operat*:ti or excis*:ti or extract*: ti or remov*:ti or dissect*:ti or ablat*: ti or coblat*:ti or laser*:ti)
#10 (#8 OR #9)
#11 (#7 AND #10)
#12 (#4 OR #11)
#13 (nose OR nasal) NEAR (symptom* OR discharg* OR secret* OR obstruct*)
#14 rhinorrhea OR rhinorrhoea
#15 MeSH descriptor Nasal Obstruction explode all trees
#16 airway* AND obstruct*
#17 breath* AND impair*
#18 MeSH descriptor Otitis Media explode all trees
#19 middle NEXT ear NEXT (infect* OR inﬂam* OR disease*)
#20 otitis OR aom OR ome
#21 glue AND ear
#22 (#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21)
#23 (#12 AND #22)
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PubMed
EMBASE (Ovid)
#1 “Adenoidectomy”[Mesh]
#2 “Adenoids/surgery”[Mesh]
#3 adenoidectom* [tiab] OR adenotonsillectom* [tiab] OR adenotonsilectom* [tiab]OR “adeno tonsillectomy” [tiab]OR
“adeno tonsilectom” [tiab]
#4 #1 OR #2 OR #3
#5 “Adenoids”/[Mesh]
#6 adenoid* [tiab] OR adenotonsil* [tiab]
#7 #5 OR #6
#8 “Surgical Procedures, Operative”[Mesh]
#9 “surgery”[Subheading]
#10 surg* [tiab] OR operat* [tiab] OR excis* [tiab] OR extract* [tiab] OR remov* [tiab] OR dissect* [tiab] OR ablat* [tiab]
OR coblat* [tiab] OR laser* [tiab]
#11 #8 OR #9 OR #10
#12 #7 AND #11
#13 #4 OR #12
#14 (nose [tiab] OR nasal [tiab]) AND (symptom* [tiab] OR discharg* [tiab] OR secret* [tiab] OR obstruct* [tiab])
#15 rhinorrhea [tiab] OR rhinorrhoea [tiab]
#16 “Nasal Obstruction”[Mesh]
#17 airway* [tiab] AND obstruct* [tiab]
#18 breath* [tiab] AND impair* [tiab]
#19 “Otitis Media”[Mesh]
#20 middle [tiab] AND ear [tiab] AND (infect* [tiab] OR inﬂam* [tiab] OR disease* [tiab])
#21 otitis [tiab] OR aom [tiab] OR ome [tiab]
#22 glue [tiab] AND ear [tiab]
#23 #14 OR #15 OR #16
1 adenoidectomy/
2 (adenoidectom* or adenotonsillectom* or adenotonsilectom* or “adeno tonsillectomy*” or “adeno tonsilectom*”).tw.
3 1 or 2
4 *Adenoid/
5 (adenoid* or adenotonsil*).ti.
6 4 or 5
7 (surg* or operat* or excis* or extract* or remov* or dissect* or ablat* or coblat* or laser*).ti.
8 exp *Surgery/
9 8 or 7
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Cumulative Index to Nursing and Allied Health Literature
(CINAHL) (EBSCOhost)
10 6 and 9
11 3 or 10
12 nose obstruction/or rhinorrhea/
13 *airway obstruction/or *upper respiratory tract obstruction/
14 ((nose or nasal) and (symptom* or discharg* or obstruct* or secret*)).tw.
15 (rhinorrhea or rhinorrhoea).tw.
16 (airway* and obstruct*).tw.
17 (breath* and impair*).tw.
18 exp Middle Ear Disease/
19 (middle and ear and (infect* or inﬂamm* or disease*)).tw.
20 (otitis or aom or raom or ome).tw.
21 (glue and ear).tw.
22 21 or 17 or 12 or 20 or 15 or 14 or 18 or 13 or 16 or 19
23 22 and 11
S1 (MH “Adenoidectomy”)
S2 (MH “Adenoids/SU”)
S3 adenoidectom* or adenotonsillectom* or adenotonsilectom* or “adeno tonsillectomy*” or “adeno tonsilectom*”
S4 (MM “Adenoids”)
S5 TI adenoid* or adenotonsil*
S6 TI surg* or operat* or excis* or extract* or remov* or dissect* or ablat* or cobalt* or laser*
S7 (MH “Surgery, Operative”)
S8 S6 or S7
S9 S4 or S5
S10 S8 and S9
S11 S1 or S2 or S3 or S10
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Web of Science
Bioscience Information Service previews/CAB Abstracts (Ovid)
#1 TS=(adenoidectom* or adenotonsillectom* or adenotonsilectom* or “adeno tonsillectomy*” or “adeno
tonsilectom*”)
#2 TI=(adenoid* or adenotonsil*)
#3 TI=(surg* or operat* or excis* or extract* or remov* or dissect* or ablat* or coblat* or laser*)
#4 #2 AND #3
#5 #1 OR #4
#6 TS=((nose or nasal) and (symptom* or discharg* or obstruct* or secret*))
#7 TS=(rhinorrhea or rhinorrhoea)
#8 TS=(airway* and obstruct*)
#9 TS=(breath* and impair*)
#10 TS=(middle and ear and (infect* or inﬂamm* or disease*))
#11 TS=(otitis or aom or raom or ome)
#12 TS=(glue and ear)
#13 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12
#14 #5 AND #13
1 (adenoidectom* or adenotonsillectom* or adenotonsilectom* or “adeno tonsillectomy*” or “adeno tonsilectom*”).tw.
2 (adenoid* or adenotonsil*).ti.
3 (surg* or operat* or excis* or extract* or remov* or dissect* or ablat* or coblat* or laser*).ti.
4 ((nose or nasal) and (symptom* or discharg* or obstruct* or secret*)).tw.
5 (rhinorrhea or rhinorrhoea).tw.
6 (airway* and obstruct*).tw.
7 (breath* and impair*).tw.
8 (middle and ear and (infect* or inﬂamm* or disease*)).tw.
9 (otitis or aom or raom or ome).tw.
10 (glue and ear).tw.
11 3 and 2
12 11 or 1
13 8 or 6 or 4 or 7 or 10 or 9 or 5
14 13 and 12
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Appendix 4 Study representatives for the included
studies (ordered alphabetically by first author)
No. Study Representative
1 Black NA, Sanderson CF, Freeland AP, Vessey MP. A randomised controlled trial of
surgery for glue ear. BMJ 1990;300:1551–6
NA Black
2 Casselbrant ML, Mandel EM, Rockette HE, Kurs-Lasky M, Fall PA, Bluestone CD.
Adenoidectomy for otitis media in 2–3-year old children. Int J Pediatr Otorhinolaryngol
2009;73;1718–24
ML Casselbrant
3 Dempster JH, Browning GG, Gatehouse SG. A randomized study of the surgical
management of children with persistent otitis media with effusion associated with
a hearing impairment. J Laryngol Otol 1993;107:284–9
GG Browning
4 Hammarén-Malmi S, Saxen H, Tarkkanen J, Mattila PS. Adenoidectomy does not
signiﬁcantly reduce the incidence of otitis media in conjunction with the insertion
of tympanostomy tubes in children who are younger than 4 years: a randomized trial.
Pediatrics 2005;116:185–9
PS Mattila
5 Koivunen P, Uhari M, Luotonen J, Kristo A, Raski R, Pokka T, et al. Adenoidectomy
versus chemoprophylaxis and placebo for recurrent acute otitis media in children
aged under 2 years: randomised controlled trial. BMJ 2004;328:487
P Koivunen
6 Kujala T, Alho OP, Luotonen J, Kristo A, Uhari M, Renko M, et al. Tympanostomy
with and without adenoidectomy for prevention of acute otitis media: a randomized
controlled trial. Pediatric Infect Dis J 2012;31:565–9
P Koivunen
7 Mattila PS, Joki-Erkkila VP, Kilpi T, Jokinen J, Herva E, Puhakka H. Prevention of
otitis media by adenoidectomy in children younger than 2 years.
Arch Otolaryngol Head Neck Surg 2003;129:163–8
PS Mattila
8 Maw AR, Herod F. Otoscopic, impedance, and audiometric ﬁndings in glue
ear treated by adenoidectomy and tonsillectomy. A prospective randomised study.
Lancet 1986;1:1399–402
Maw R, Bawden R. Spontaneous resolution of severe chronic glue ear in
children and the effect of adenoidectomy, tonsillectomy, and insertion of
ventilation tubes (grommets). BMJ 1993;306:756–60
AR Maw
9 MRC Multicentre Otitis Media Study Group. Adjuvant adenoidectomy
in persistent bilateral otitis media with effusion: hearing and revision
surgery outcomes through 2 years in the TARGET
randomised trial. Clin Otolaryngol 2012;37:107–16
MP Haggard/GG
Browning
10 Nguyen LH, Manoukian JJ, Yoskovitch A, Al Sebeih KH. Adenoidectomy:
selection criteria for surgical cases of otitis media. Laryngoscope 2004;114:863–6
JJ Manoukian
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Appendix 5 Inclusion and exclusion criteria for the
10 included studies
Study Inclusion criteria Exclusion criteria
Black 199052 Age 4–9 years; operation indication for glue
ear (secretory OM) based on the clinical
judgement of the otolaryngologist
Previous operations on tonsils, adenoids or
ears; cleft palate or any sensorineural deafness;
conditions other than glue ear, such as gross
nasal obstruction
Casselbrant
200911
Age 2–3.9 years; history of bilateral middle ear
effusion (MEE) for at least 3 months, unilateral
for ≥ 6 months or unilateral for 3 months after
extrusion of one grommet with the other still
in place and patent, and who had completed
a 10-day course of a broad-spectrum
antimicrobial agent within the past month
Previous tonsillectomy and/or adenoidectomy;
previous ear surgery other than
tympanocentesis or myringotomy with or
without tube insertion; history of seizure
disorder, diabetes mellitus, asthma requiring
daily medication or any health condition that
would make entry potentially disadvantageous
to the child; medical conditions with a
predisposition for MEE, such as cleft palate,
Down syndrome, congenital malformations of
the ear; cholesteatoma or chronic mastoiditis;
severe retraction pockets; acute or chronic
diffuse external OM; perforation of the
tympanic membrane; intracranial or
intratemporal complications of MEE; upper
respiratory tract obstruction attributable to
tonsil or adenoid enlargement or both with cor
pulmonale, sleep apnoea or severe dysphagia;
conductive hearing loss attributable to
destructive changes in the middle ear;
sensorineural hearing loss; distance from
hospital that would make follow-up difﬁcult
Dempster 199312 Age 3–12 years; otoscopic evidence of bilateral
OME with a pure-tone air conduction threshold
average over 0.5, 1 and 2 kHz of > 25 dBHL,
and with an air-bone gap over 0.5, 1 and
2 kHz of > 25 dB, and a type B tympanogram
Previous adenoidectomy or aural surgery or
additional symptoms requiring surgical
intervention, e.g. recurrent sore throat;
cleft palate
Hammarén-Malmi
200515,51
Age 1–4 years; recurrent AOM (more than
three episodes of AOM during the preceding
6 months or more than ﬁve episodes of AOM
during the preceding 12 months) or a suspicion
of chronic OME as judged by examination with
a pneumatic otoscope
Previous adenotonsillar surgery or placement of
tympanostomy tubes; children with asthma,
cleft palate or diabetes or children who were
judged to require prompt removal of adenoids
because of obstructive symptoms resulting in
continuous mouth breathing or sleep apnoea,
were excluded
Koivunen 200416 Age 10 months to 2 years; three or more
episodes of AOM in the last 6 months
Previously performed adenoidectomy or
tympanostomy tube placement; cranial
anomalies; documented immunological
disorders and ongoing antimicrobial
chemoprophylaxis
Kujala 201217 Age 10 months to 2 years; at least three AOM
episodes during the past 6 months and
residence within 25 miles of the hospital
Chronic OME; a prior adenoidectomy or
tympanostomy tubes; cranial anomalies;
documented immunological disorders or
ongoing anti-microbial prophylaxis for a
disease other than AOM
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Study Inclusion criteria Exclusion criteria
Mattila 200318 Age 1–2 years; three to ﬁve events of AOM
during the last 6 months or four to six events
of AOM during the last year
Nothing known about exclusion criteria
Maw 1986,19
199310
Age 2–9 years; persistent subjective hearing
difﬁculty; pneumatic otoscopic conﬁrmation of
bilateral effusions; symmetrical audiometric
hearing loss > 25 dB at one or more
frequencies; impedance measurements not
showing a peak A-type curve
Resolution of effusions in one or both ears
during 3 months’ preoperative follow-up;
upper airway obstruction from gross adenoidal
hyperplasia; parents’ refusal of randomisation;
reappraisal of audiometric data, either because
the loss was asymmetrical or because of
superadded sensorineural loss; loss to
preoperative follow-up; the child was found to
be ineligible for inclusion because at the
moment of operation he or she did not have
bilateral effusion
MRC Multicentre
Otitis Media
Study Group
201220
Age 3.5–7 years; on two qualifying visits,
3 months apart, a bilateral B + B or B + C2
tympanogram combination (modiﬁed Jerger)
and better-ear hearing loss ≥ 20 dBHL
averaged across 0.5, 1, 2 and 4 kHz and an
air-bone gap > 10 dB; non-independence of
these markers entails that the conjunction is
not greatly more stringent than the 20-dBHL
component alone
Previous ear surgery; craniofacial structural
abnormalities; severe systemic disease
(e.g. diabetes) and non-OME ear disease
(e.g. perforation). Optional exclusion: hearing
loss ≤ 40 dBHL in the better-hearing ear55
Nguyen 200421 Age 18 months to 18 years; following
indications for grommet insertion as the ﬁrst
surgical treatment of OM: (1) recurrent OM
with more than three episodes during the
preceding 6 months or more than four during
the preceding 12 months, (2) OME persisting
for > 3 months or producing a conducting
hearing loss > 30 dB with a type B
tympanogram or (3) both
Previous grommet insertion; Down syndrome;
craniofacial anomalies such as cleft palate;
immune deﬁciency; bleeding disorders; ciliary
dyskinesia; follow-up period of < 6 months
MEE, middle ear effusion.
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Appendix 6 Indication for surgery sorted by
age range
Study Indication for surgery
Age range
Eligible for inclusion Empirical data
Koivunen 200416 Recurrent AOM 10 months to 2 years 0.8–2.0 years
Kujala 201217 Recurrent AOM 10 months to 2 years 0.5–2.0 years
Mattila 200318 Recurrent AOM 1–2 years 1.0–2.0 years
Hammarén-Malmi 200515,51 Both recurrent AOM
and/or persistent OME
1–4 years 1.0–4.0 years
Nguyen 200421 Both recurrent AOM
and/or persistent OME
18 months to 18 years 1.5–9.6 years
Casselbrant 200911 Persistent OME 2–3.9 years 2.0–4.0 years
Maw 1986,19 199310 Persistent OME 2–9 years 2.5–8.7 years
Dempster 199312 Persistent OME 3–12 years 4.0–9.0 years
MRC Multicentre Otitis
Media Study Group 201220
Persistent OME 3.5–7 years 3.5–7.0 years
Black 199052 Persistent OME 4–9 years 3.4–9.8 years
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Appendix 7 Definitions of recurrent acute otitis
media and persistent otitis media with effusion as used
in the included studies
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unavailable studies
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Appendix 9 Inclusion and exclusion criteria of the
five eligible but unavailable studies
Study Inclusion criteria Exclusion criteria
Gates 198714 Age 4–8 years; bilateral chronic effusion
diagnosed by an otoscopist
History of previous tonsil or adenoid surgery;
placement of grommets (within 2 years); cleft
palate; any severe chronic illness; advanced or
irreversible structural damage of the
tympanum (such as cholesteatoma,
perforation, atelectasis)
Paradise 199023 Age 1–15 years; (1) a history of persistent and/
or recurrent OM; (2) thereafter received
tympanostomy tube placement in one or both
ears on one or more occasions; and (3)
developed, after extrusion and within the year
that preceded enrolment, one or more
additional, well-documented episodes of either
suppurative (A)OM or non-suppurative (A)OM
Overt or submucous palatal clefts
Paradise 199922 Age 3–15 years; (1) at least three episodes of
AOM during the preceding 6 months, or at
least four episodes during the preceding 12
months including at least one episode during
the preceding 6 months, with at least one of
the episodes having been documented with a
recorded description of symptoms and
tympanic membrane ﬁndings or conﬁrmed by
tympanometry or myringotomy; or (2) middle
ear effusion in one or both ears extending
over at least 180 days during the preceding
year and documented by at least two clinical
observations at least 6 months apart, the most
recent by a study team clinician and/or
conﬁrmed by tympanometry
Overt or submucous palatal clefts or previous
grommet placement
Roydhouse 198024 Age 2–14 years; OME diagnosed on clinical
grounds and with impedance audiometry
A primary bias towards recurrent tonsillitis
Rynnel-Daggöö
198725
Age < 12 years; recurrent serous/purulent OM;
frequent upper airway infections and
nasal obstruction
Severe nasal obstruction; previous operation
performed; refused operation by parents;
recurring adenoids; diabetes; or
administrative mishaps
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Appendix 10 Number and percentage of children
failing according to each component of the composite
end point
Recurrent
AOM,
n/N (%)
Persistent
OME,
n/N (%)
Improvement in
hearing level
< 10 dB, n/N (%)
Additional
surgery,
n/N (%)
Composite
end point,
n/N (%)
Adenoidectomy with unilateral or bilateral grommets
Black 199052 – 39/75 (52.0) – 1/75 (1.3) 40/75 (53.3)
Casselbrant 200911 0/31 (0.0) 0/24 (0.0) – 1/32 (3.1) 1/32 (3.1)
Dempster 199312 – 24/37 (64.9) 7/37 (18.9) NA 25/37 (67.6)
Hammarén-Malmi
200515,51
17/102 (16.7) – – 10/110 (9.1) 22/110 (20.0)
Kujala 201217 4/101 (4.0) 0/40 (0.0) – 6/101 (5.9) 9/101 (8.9)
Mattila 200318 4/45 (8.9) – – 0/73 (0.0) 4/73 (5.5)
Maw 1986,19 199310 – 52/83 (62.7) 18/49 (36.7) 7/80 (8.8) 56/83 (67.5)
MRC Multicentre
Otitis Media Study
Group 201220
10/117 (8.5) 38/114 (33.3) 30/111 (27.0) 2/128 (1.6) 61/128 (47.7)
Nguyen 200421 0/17 (0.0) 0/13 (0.0) – 0/33 (0.0) 0/33 (0.0)
Adenoidectomy alone
Casselbrant 200911 1/35 (2.9) 0/29 (0.0) – 6/35 (17.1) 7/35 (20.0)
Koivunen 200416 16/60 (26.7) 0/60 (0.0) – 5/60 (8.3) 20/60 (33.3)
Unilateral or bilateral grommets
Black 199052 – 39/74 (52.7) – 7/77 (9.1) 44/77 (57.1)
Casselbrant 200911 0/31 (0.0) 0/27 (0.0) – 3/31 (9.7) 3/31 (9.7)
Dempster 199312 – 21/35 (60.0) 11/35 (31.4) NA 22/35 (62.9)
Hammarén-Malmi
200515,51
7/96 (7.3) – – 13/107 (12.1) 17/107 (15.9)
Kujala 201217 9/98 (9.2) 0/48 (0.0) – 13/98 (13.3) 17/98 (17.3)
Mattila 200318 3/32 (9.4) – – 5/57 (8.8) 5/57 (8.8)
Maw 1986,19 199310 – 67/83 (80.7) 28/56 (50.0) 31/83 (37.3) 72/83 (86.7)
MRC Multicentre
Otitis Media Study
Group 201220
15/119 (12.6) 44/113 (38.9) 47/110 (42.7) 4/126 (3.2) 71/126 (56.3)
Nguyen 200421 0/28 (0.0) 0/19 (0.0) – 0/37 (0.0) 0/37 (0.0)
Non-surgical
Koivunen 200416 41/120 (34.2) 0/120 (0.0) – 30/120 (25.0) 54/120 (45.0)
Kujala 201217 17/101 (16.8) 0/21 (0.0) – 23/101 (22.8) 30/101 (29.7)
MRC Multicentre
Otitis Media Study
Group 201220
19/112 (17.0) 83/112 (74.1) 40/100 (40.0) 43/122 (35.2) 109/122 (89.3)
NA, surgery not allowed during follow-up.
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Appendix 11 Significant interaction effects for
adenoidectomy with or without grommets compared
with non-surgical treatment or grommets only
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Appendix 12 Significant interaction effects for
adenoidectomy with unilateral or bilateral grommets
compared with non-surgical treatment
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Appendix 16 Per-protocol and as-treated analysis
for the subgroup analysis of the main comparison
between adenoidectomy with or without grommets
and non-surgical treatment or grommets only
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Appendix 17 Recommendations for
further research
Introduction
As requested in the brief, we have summarised the outstanding research questions based on the speciﬁc
project and its position in the range of systematic reviews that it complements, covering grommets and
adenoidectomy in children with OME (‘glue ear’), and recurrent upper respiratory symptoms.
Several speciﬁc recommendations are made and these follow the generic answers to the questions posed.
Brieﬂy explain why this research or evidence is important to
the NHS or for wider public health
Upper respiratory tract infections are the most common infectious diseases in children. It is one
of the most common diagnoses in primary care. Although many infections are self-limiting,
some require treatment.
What is the patient/population group likely to beneﬁt from this
research and why/how will they beneﬁt?
Children with recurrent upper respiratory tract symptoms – especially nasal obstruction and discharge and
symptoms of recurrent AOM and chronic OME – are often considered for surgical intervention (grommets,
adenoidectomy and tonsillectomy). Alternatively they are treated non-surgically or are simply ‘actively
monitored’ with a period of ‘watchful waiting’.
In what setting will the outcome of the research be delivered
(e.g. primary care, the community)?
The optimal management of the population comprising children with recurrent upper respiratory tract
symptoms needs to be considered on a population basis rather than in terms of distinct strategies in
primary or secondary care. We know that expectations set in primary care can have profound effects on
management choices in secondary care. Shared decision-making processes, based on outcomes important
to patients, must be supported by relevant evidence in all health-care settings.
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Important research questions
Question 1: what are the best methods of selecting, developing and
administering patient-reported outcome measures to assess the value of
treatments for children with persistent otitis media with effusion and
recurrent acute otitis media and upper respiratory tract infections?
Notes
This requires:
l A systematic literature review to inform the selection of PROMs in children with ear, nose and throat
(ENT) infections.
l An evaluation of the role of PROMs in stimulating shared decision-making.
l The design of a ‘PROM-related intervention’ that might be used with the parents and carers of children
with ENT infections who are faced with making decisions about the alternative options of surgical and
non-surgical management. This PROM-related intervention should be shaped by a scoping exercise to
look at which questionnaire(s) to use, how and when to administer and score them and who to
administer them to, how to report and present the results to children and parents/carers and how to
respond to issues raised.
l An evaluation of the effectiveness of the use of PROMs in this way in children with ENT infections in a
cluster randomised trial.
Question 2: what is the clinical effectiveness and cost-effectiveness of
hearing aids (air or bone conduction) for children with different degrees of
persistence and severity of hearing loss associated with otitis media with
effusion?
Question 3: why do treatment preferences (both professionals’ and
parents’/carers’ preferences) vary so much?
Notes
Further studies are required of the practice variation seen in the management of (recurrent) AOM,
(persistent) OME and (recurrent) upper respiratory tract infections. Research should include the linking of
existing data sets [including Flu Watch (see www.ﬂuwatch.co.uk), the Clinical Practice Research Datalink
(CPRD) (see www.cprd.com) and Hospital Episode Statistics (HES) (see www.hscic.gov.uk/hes)] and
qualitative studies.
Question 4: why does adenoidectomy work in different subgroups at
different ages?
Notes
Age may be a proxy measure for some maturational physiological changes that could be better
understood.
Further studies are required into the aetiology and prognostics of (persistent) OME and (recurrent) AOM
and upper respiratory tract infections attributable (rightly or wrongly) to adenoid hypertrophy or infection.
Research enquiries should include risk factors such as reﬂux and the microbiome of the upper airways.
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Question 5: special populations – children with Down syndrome, cleft
palate or developmental problems
Notes
All of the existing systematic reviews (and, as far as we are aware, all RCTs) exclude children with these
special conditions. The question therefore remains: what are the most clinically effective and cost-effective
treatment strategies for children with recurrent AOM and persistent OME who also have Down syndrome,
cleft palate or developmental problems?
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